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ABSTRACT
BIOMARKER DISCOVERY OF LIVER DISEASES USING MASS
SPECTROMETRY-BASED METABOLOMICS
Xue Shi
November 20, 2014

Metabolomics has emerged as one of the latest of the "-omics" disciplines that can detect
metabolite biomarkers in biological samples. The diverse characteristics of metabolites
make the analytical platform challenging in metabolomics. Two bioanalytical platforms
were developed in this study to investigate metabolite abundance changes under different
biological conditions. We first developed a bioanalytical platform that coupled linear trap
quadruple - Fourier transform ion cyclotron mass spectrometer (LTQ-FTICR MS) with
direct infusion chip-based nano-electrospray ionization (DI-nESI) and applied it to study
polychlorinated biphenyls (PCB) effects on non-alcoholic fatty liver disease (NAFLD).
We also employed this platform in conjunction with in vivo metabolite deuterium
labeling to study whether chronic alcohol exposure disturbs lipid homeostasis by
analyzing triacylglycerol regulation alteration in adipose tissue and liver tissue. We
further developed a comprehensive two-dimensional gas chromatography time-of-flight
mass spectrometry (GC×GC-TOF MS) platform for metabolomic profiling and applied it
to study the effects of arsenic exposure in a mouse model of diet-induced fatty liver
disease, as well as the effects of Lactobacillus rhamnosus GG on alcoholic fatty liver
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disease (AFLD) in mice. The results of our metabolomics analyses agreed with the results
of histological studies and provided molecular level information for further understanding
the mechanisms of liver diseases.

vii

TABLE OF CONTENTS
LIST OF FIGURES .......................................................................................................... xii
LIST OF TABLES ............................................................................................................ xv
CHAPTER 1 ....................................................................................................................... 1
INTRODUCTION .............................................................................................................. 1
1.1.

Metabolomics ....................................................................................................... 1

1.1.1.

Untargeted Metabolomics ............................................................................. 2

1.1.2.

Targeted Metabolomics ................................................................................ 2

1.1.3.

Stable Isotope Assisted Metabolomics (SIAM) ............................................ 3

1.2.

Analytical Platforms for Metabolomics ............................................................... 4

1.2.1.

Nuclear Magnetic Resonance (NMR) Spectroscopy .................................... 4

1.2.2.

Direct Infusion Mass Spectrometry (DI-MS) ............................................... 5

1.2.3.

Liquid Chromatography Mass Spectrometry (LC-MS) ................................ 6

1.2.4.

Gas Chromatography Mass Spectrometry (GC-MS) .................................... 7

1.3.

Liver Disease ........................................................................................................ 8

1.4.

Objectives of This Dissertation .......................................................................... 10

CHAPTER 2 ..................................................................................................................... 11
METABOLOMIC ANALYSIS OF THE EFFECTS OF POLYCHLORINATED
BIPHENYLS IN NON-ALCOHOLIC LIVER DISEASE ............................................... 11
2.1.

Introduction ........................................................................................................ 11

2.2.

Experimental ...................................................................................................... 13

2.2.1.

Animals and Diets ....................................................................................... 13

2.2.2.

Liver Histological Studies........................................................................... 14

2.2.3.

Metabolite Sample Preparation ................................................................... 14

2.2.4.

Spike-in Samples ........................................................................................ 15

2.2.5.

FTICR-MS and LTQ-MS/MS Analysis...................................................... 16

2.2.6.

Data Analysis .............................................................................................. 16

viii

2.3.

Results and Discussion ....................................................................................... 18

2.3.1.

PCB 153 Worsened Steatosis in Mice Fed a High Fat Diet (HFD) ............ 18

2.3.2.

Evaluation of Metabolomics Analysis Platform ......................................... 19

2.3.3.

Metabolite Identification ............................................................................. 22

2.3.4.

Metabolite Quantification ........................................................................... 24

2.3.5.

Ingenuity Pathway Analysis (IPA) ............................................................. 32

2.4.

Conclusions ........................................................................................................ 38

CHAPTER 3 ..................................................................................................................... 39
CHRONIC ALCOHOL EXPOSURE DISTURBS LIPID HOMEOSTASIS AT THE
ADIPOSE-LIVER AXIS: ANALYSIS OF TRIACYLGLYCEROLS USING
HIGH-RESOLUTION MASS SPECTROMETRY IN COMBINATION WITH IN VIVO
METABOLITE DEUTERIUM LABELING ................................................................... 39
3.1.

Introduction ........................................................................................................ 39

3.2.

Experimental ...................................................................................................... 41

3.2.1.

Animals and Treatments ............................................................................. 41

3.2.2.

Tissue Sample Preparation .......................................................................... 42

3.2.3.

FT-MS and LTQ-MS/MS Analysis ............................................................ 43

3.2.4.

Metabolite Quantification ........................................................................... 43

3.2.5.

Metabolite Identification ............................................................................. 44

3.2.6.

Measurements of Liver Steatosis and Routine Parameters ......................... 45

3.3.

Results ................................................................................................................ 45

3.3.1.

Metabolite Identification ............................................................................. 45

3.3.2.

Statistical Significance Tests ...................................................................... 49

3.3.3.

Temporal Analysis ...................................................................................... 51

3.3.4.

Alterations of Hepatic Neutral Lipid and WAT Mass ................................ 54

3.3.5.

Routine Parameters ..................................................................................... 57

3.4.

Discussion .......................................................................................................... 58

3.4.1.

Biological Experiment Design .................................................................... 59

3.4.2.

Statistical Significance Tests ...................................................................... 59

3.4.3.

Temporal Analysis ...................................................................................... 60

3.4.4.

WAT Dysfunction and Fatty Liver ............................................................. 61

ix

3.4.5.
3.5.

Alcohol-induced Hepatic Lipid Dyshomeostasis........................................ 62

Conclusions ........................................................................................................ 63

CHAPTER 4 ..................................................................................................................... 65
THE EFFECTS OF CHRONIC ARSENIC EXPOSURE IN A MOUSE MODEL OF
DIET-INDUCED FATTY LIVER DISEASE .................................................................. 65
4.1.

Introduction ........................................................................................................ 65

4.2.

Experimental ...................................................................................................... 68

4.2.1.

Materials and Reagents ............................................................................... 68

4.2.2.

Spiked-in Samples ...................................................................................... 68

4.2.3.

Animals and Diets ....................................................................................... 70

4.2.4.

Metabolite Sample Preparation from Mouse Liver .................................... 71

4.2.5.

GCGC–TOF MS Analysis ........................................................................ 71

4.2.6.

Data Analysis .............................................................................................. 72

4.2.7.

Metabolite Relative Quantification ............................................................. 73

4.3.

Results ................................................................................................................ 74

4.3.1.

Metabolite Identification ............................................................................. 77

4.3.2.

Metabolite Quantification ........................................................................... 79

4.3.3.

Analysis of Spike-in Samples ..................................................................... 84

4.4.

Discussion .......................................................................................................... 89

4.5.

Conclusions ........................................................................................................ 96

CHAPTER 5 ..................................................................................................................... 98
HEPATIC AND FECAL METABOLOMIC ANALYSIS OF THE EFFECTS OF
LACTOBACILLUS RHAMNOSUS GG ON ALCOHOLIC FATTY LIVER DISEASE
IN MICE ........................................................................................................................... 98
5.1.

Introduction ........................................................................................................ 98

5.2.

Experimental Methods ....................................................................................... 99

5.2.1.

Animals and Diets ....................................................................................... 99

5.2.2.

Liver Oil Red O Staining and Liver Total Free Fatty Acid Analysis ....... 100

5.2.3.

Metabolite Sample Preparation ................................................................. 100

5.2.4.

GCGC–TOF MS Analysis ...................................................................... 101

5.2.5.

Data Analysis ............................................................................................ 102

x

5.3.

Results .............................................................................................................. 103

5.4.

Discussion ........................................................................................................ 114

5.5.

Conclusions ...................................................................................................... 120

CHAPTER 6 ................................................................................................................... 121
SUMMARY AND CONCLUSIONS ............................................................................. 121
REFERENCES ............................................................................................................... 128
APPENDIX ..................................................................................................................... 157
CURRICULUM VITAE ................................................................................................. 162

xi

LIST OF FIGURES

Figure 1. PCB 153 Structure ............................................................................................. 12
Figure 2. PCB 153 worsened hepatic steatosis in mice fed a high fat diet. (A) Oil Red O
staining of hepatic sections established the occurrence of micro-vesicular steatosis in the
HFD+PCB 153 mice. (B) The same group of mice also showed macro-vesicular steatosis
by H&E staining. .............................................................................................................. 19
Figure 3. Relationship between the cutoff value of the p-value of t-test and the values of
TPR, PPV, and F1 during the analysis of the spiked-in experiments. (A) TPR (B) PPV (C)
F1 ...................................................................................................................................... 22
Figure 4. An example of identifying metabolites using MS/MS information. The
metabolite ion m/z value was measured using FTICR-MS as 156.0773. (A) is the
experiment MS/MS spectrum of the metabolite ion. (B) is the matching result of the
metabolite between the experiment MS/MS spectrum and the in silico MS/MS spectrum
of the same metabolite ion generated by Mass Frontier 7.0. The matched fragment ions
are highlighted in red and the unmatched fragment ions in black. (C) is the MS/MS
spectrum of the L-histidine standard................................................................................. 24
Figure 5. The peak area distribution of metabolite fucose 1-phosphate in the HFD
samples (red triangles) and in the HFD+PCB 153 samples (blue stars). The abundance
test (pairwise two-tail t-test) shows that the regulation of this metabolite in the
HFD+PCB 153 group is decreased with a fold change of 2.65 and a p-value of 4.84×10–4.
........................................................................................................................................... 26
Figure 6. Erythronic Acid Structure.................................................................................. 27
Figure 7. IPA proof-of-knowledge characterization of the metabolic networks in mouse
liver affected by PCB 153.The dashed line indicates indirect interactions between
metabolites while the solid line means a direct metabolite interaction. Filled circles
represent metabolites discovered in this work and the color of each filled circle represents
the direction and magnitude of fold-changes. Green color means down-regulated, red
color means up-regulated. ................................................................................................. 35
Figure 8. An example of identifying a deuterium incorporated metabolite using MS/MS
information.The metabolite ion m/z value was measured on FTICR-MS as 904.74066. (A)
is the experimental MS/MS spectrum of non-deuterated metabolite. (B) is the matching
result of the non-deuterated metabolite between the experiment MS/MS spectrum and the
theoretical MS/MS spectrum generated by Mass Frontier. The matched fragment ions are

xii

highlighted in red and the not matched ions in black. (C) is the MS/MS spectrum of
deuterium incorporated metabolite. .................................................................................. 46
Figure 9. Sample concentration changes of metabolite in two different physiological
conditions.The abundance test (pair-wise two-tail t-test) shows that the concentration of
this metabolite in the test cohort is increased with a fold change of 2.8 and a p-value of
1.4×10-5. This metabolite was further identified as TG(16:0/18:2/20:4)[iso6] by MS/MS
analysis. ............................................................................................................................. 49
Figure 10. Sample time course trajectories of deuterium labeled triacylglycerols detected
in liver, eWAT and sWAT samples.(A) TG(16:0/18:2/20:4)[iso6] with one 2H label and
one Na+ as adduct ion in liver samples. (B) TG(16:0/16:1/16:1)[iso3] with one 2H label
and an adduct ion of Na+ eWAT samples. (C) TG(16:0/16:0/18:1)[iso3] with one 2H label
and an adduct ion of Na+ in sWAT samples ..................................................................... 53
Figure 11. Time course trajectory of triacylglycerol TG(16:0/18:2/20:4)[iso6] without
any deuterium labeling in liver samples. .......................................................................... 53
Figure 12. Time course changes of hepatic lipid content. Hepatic neutral lipid detected by
Oil red O staining of cryostat liver sections. Alcohol exposure increased hepatic neutral
lipid (lipid droplets) gradually along the 4 weeks of experiment. .................................... 55
Figure 13. Time course changes of WAT tissues.(A) WAT mass. The weights of both
eWAT and sWAT in control mice increased gradually during the 4 weeks of experiment.
However, the alcohol-fed mice did not show weight change in both eWAT and sWAT at
either 2 weeks or 4 weeks. (B) WAT to body weight ratio (%). Data are expressed as
mean ±SD (n=6-8). Statistical differences were analyzed by ANOVA followed by
Bonferroni post hoc comparison, and means without a common letter differ at p<0.05. . 56
Figure 14. Workflow of metabolomics Study by GC×GC-TOF MS................................ 75
Figure 15. Sample GC×GC–TOF MS chromatograms of metabolite extract from mouse
liver. The x-axis is the first dimension retention time 1tR in seconds. The y-axis is the
second dimension retention time 2tR in seconds. The color bar shows the signal intensity
of each peak plotted on the chromatogram in total ion current. ....................................... 76
Figure 16. Abundance distribution of metabolite glycine in the samples of HFD+As
group and HFD group.The abundance test (pairwise two-tail t-test) shows that the
regulation of this metabolite in the HFD+As group is decreased with a fold change of 1.7
and a p-value of 5.0×10-3 comparing with HFD group..................................................... 80
Figure 17. Boxplot of peak area of the 28 spiked-in metabolites in G10 before reference
spectrum-based peak area conversion (A) and after the reference spectrum-based peak
area conversion (B). + refers to the values of peak area considered as outliers. .............. 86
Figure 18. The receiver operating characteristic (ROC) curve of the spike-in data. The
area under curve (AUC) of the three comparisons is 0.87, 0.71, and 0.81 for G20 vs. G10,
G40 vs. G10 and G40 vs. G20, respectively. .................................................................... 88
Figure 19. Clustering analysis of the four sample groups using fuzzy C mean algorithm.
The input data were the abundance of all metabolites that were detected with significant

xiii

regulation changes between two or more sample groups when the FDR threshold q≤0.2.
(A) depicts the clustering results of all four sample groups. The overall clustering
accuracy reached 0.70. (B) displays the clustering accuracy between two sample groups.
........................................................................................................................................... 90
Figure 20. Sample GC×GC–TOF MS chromatogram of metabolite extract from mouse
fecal samples. The x-axis is the first dimension retention time 1tR in seconds. The y-axis
is the second dimension retention time 2tR in seconds. The color bar shows the signal
intensity of each peak plotted on the chromatogram in total ion current........................ 105
Figure 21. Abundance distribution of metabolite hexanoic acid in four sample groups. (A)
is in liver samples, and (B) is in fecal samples. .............................................................. 108
Figure 22. Effect of LGGs on hepatic free fatty acid levels. Stars * refer to the amount of
total free fatty acids between two sample groups is significantly different with p < 0.05.
......................................................................................................................................... 111
Figure 23. Effect of LGGs on liver fat accumulation. Hepatic cryosections were Oil red O
stained and images were acquired by light microscopy. ................................................. 114
Figure 24. Clustering of metabolite profiles using partial least squares discriminant
analysis (PLSDA). (A) is the clustering result of metabolite profiles of all liver samples
and (B) is the clustering result of all fecal samples. ....................................................... 115

xiv

LIST OF TABLES
Table 1. Metabolites detected with significant abundance changes between the HFD
group and the HFD+PCB 153 group. ............................................................................... 28
Table 2. Metabolites detected with significant abundance changes between the CD+PCB
153 group and the HFD+PCB 153 group. ........................................................................ 30
Table 3. Metabolites detected with significant abundance changes between the CD group
and the HFD group............................................................................................................ 31
Table 4. List of triacylglycerols in liver identified with significant concentration changes
between the control cohort and the test cohort at two and four weeks. ............................ 50
Table 5. List of triacylglycerols in sWAT and eWAT identified with significant
concentration changes between the control cohort and the test cohort at two and four
weeks................................................................................................................................. 57
Table 6. Body weight, liver weight and plasma parameters of the control cohort and the
test cohort at two and four weeks. .................................................................................... 58
Table 7. Metabolites with significance abundance difference between sample groups
HFD and LFD. .................................................................................................................. 82
Table 8. Metabolites with significance abundance difference between sample groups
LFD+As and LFD. ............................................................................................................ 83
Table 9. Metabolites with significance abundance difference between sample groups
HFD+As and HFD. ........................................................................................................... 84
Table 10. The number of metabolites with significant differences between sample groups
with different values of FDR threshold. It should be noted that the number of metabolites
detected with significant difference between sample groups are different from these listed
in Tables 7, 8, 9. The number of metabolites listed in this table was directly calculated
from the alignment table. That is the identifications of these compounds were not yet
confirmed using the methods described in section 4.3.1. ................................................. 91
Table 11. Metabolites with significant changes of abundance level among the four liver
sample groups. ................................................................................................................ 109
Table 12. Metabolites with significant change of abundance level among four fecal
sample groups. ................................................................................................................ 112

xv

CHAPTER 1
INTRODUCTION
1.1. Metabolomics
Metabolomics is the study of biochemical process involving small-molecule metabolites
in a biological system. It aims to simultaneously measure and interpret the complex
time-related concentration, activity, and flux of all metabolites present in metabolome. In
contrast to classical biochemical approaches that often focus on a single metabolite,
metabolomics reveals biochemical activities of a broad range of small molecules such as
lipids, amino acids, sterols, organic acids, carbohydrates, and vitamins and as such
provides a comprehensive overview of the impact of the pathophysiological processes or
pharmacological interventions of interest on metabolism and metabolic dynamics[1].
Even though one still does not know how many types of metabolites are present in the
metabolome, the human metabolome database (HMDB) has collected 41,808 metabolite
entries[2]. Metabolites have a wide range of molecular weights and a large variation in
concentration. Metabolites can be polar or nonpolar, as well as organic or inorganic
molecules. Also the metabolome is much more dynamic than proteome and genome,
which makes the metabolome more time sensitive. The large number of metabolites and
diverse characteristics of metabolites make the chemical separation the most challenging
technical step in metabolomics.
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With the extreme complexity of metabolome, metabolomics becomes an interdisciplinary
field of science, which combines biology, chemistry, mathematics, computer science,
statistics with biomedical sciences. Metabolomics studies can be divided into three
analytical approaches: untargeted metabolomics, targeted metabolomics, and stable
isotope assisted metabolomics.

1.1.1.

Untargeted Metabolomics

Untargeted metabolomics intends the comprehensive analysis of all measurable
metabolites in a sample, such as tissues (e.g., liver, heart, lung, muscle, kidney), biofluids
(e.g., blood, serum ,plasma, urine, bile and saliva), cell lines, feces or volatile organic
compounds (e.g., those found in breath). This approach is mainly used to investigate the
regulation alteration of all detectable metabolites in metabolome. A suite of
bioinformatics tools are then employed to deconvolute the instrumental data, perform
metabolite identification, quantification, network association analysis and pathway
analysis[3-5]. Untargeted metabolomics is mainly used for metabolite biomarker
discovery, disease diagnosis, indication of the disease mechanisms, and monitoring
responses to therapy, etc.

1.1.2.

Targeted Metabolomics

Targeted metabolomics measures predefined groups of chemically characterized and
biochemically annotated metabolites. It is often used to determine relative abundance and
concentrations of a limited number of known metabolites. By analyzing the known
metabolites, predefined metabolite-specific signals are measured in biological samples,
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using selected reaction monitoring (SRM) by tandem mass spectrometry (MS/MS)[6], or
selected ion recording (SIR) by gas chromatography mass spectrometry (GC-MS)[7].

1.1.3.

Stable Isotope Assisted Metabolomics (SIAM)

All metabolites are associated with each other in the metabolome to form a large network
of molecular reactions. The outputs from one enzymatic biochemical reaction are inputs
to another. If multiple pathways result in the same product metabolite, the measured
abundance of this metabolite by untargeted metabolic profiling or targeted metabolomics
will be the summed abundance of this metabolite in all metabolic pathways. Therefore,
the abundance measurement alone is frequently insufficient to determine whether and
where a dysregulation took place, and the importance of the individual roles may be
misinterpreted or lost.
SIAM uses stable isotope tracers (e.g.

13

C or

15

N) to support studies of biochemical

mechanisms[8-10]. For example, when a primary substrate such as

13

C-glucose is added

to a biological system, the relative abundances of formation of particular isotopologues
(metabolites that differ only in isotopic composition) of metabolic intermediates from
13

C-labeled precursors in living cells provide information on the routes taken by the

initial

13

C-atoms. The unique isotopologue patterns of metabolic products reflecting the

biosynthetic history of the metabolite under study, i.e., SIAM follows the fate of each
atom and its incorporation into a multitude of metabolites produced from the labeled
tracer and therefore helps identify and quantify stable isotope labeled molecules and leads
to exact biochemical pathway assignment.
While SIAM is able to differentiate the biochemical source of a metabolite, the coverage
of metabolites by SIAM is limited to the precursor molecule(s). The metabolites that do
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not inherent labeled atoms, i.e., heavy atoms, from the precursor molecules will not be
studied. Another disadvantage of SIAM is that it requires much improved bioinformatics
tools to decipher the biochemical information from the experimental data. For example,
analysis of unlabeled samples have to be performed to limit the search space of
metabolite identification; two dimensional nuclear magnetic resonance (NMR) data have
to be used to determine the positions of labeled atoms in a metabolite. The low sensitivity
of NMR induces a significant number of isotopologues without chemical structure
information.

1.2. Analytical Platforms for Metabolomics
Owing to the significant complexity of the metabolome, there is nosingle instrument that
can analyze all metabolites simultaneously. Several types of instruments have been
utilized to analyze metabolites, including nuclear magnetic magnetic resonance
spectroscopy(NMR)[11-17], gas chromatography mass spectrometry GC-MS[18-25] and
liquid chromatography mass spectrometry (LC-MS)[26-29]. Each type of instrumental
analysis affords limited coverage of the metabolites and therefore, only provides a partial
metabolite profile of each sample. The development of comprehensive analytical
platforms by integrating the modern instrumental analytical approaches has unraveled the
ideal outcomes in metabolomics, and is beneficial to increase the coverage of metabolites
that cannot be achieved by a single analytical platform[30].

1.2.1.

Nuclear Magnetic Resonance (NMR) Spectroscopy

Nuclear magnetic resonance spectroscopy is a technique that exploits magnetic properties
of certain atomic nuclei. It determines the physical and chemical properties of atoms in
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each molecule. Suitable samples range from small compounds analyzed with one
dimensional proton or

13

C NMR spectroscopy to large proteins or nucleic acids using

even four dimensional techniques. NMR spectra are unique and often highly predictable
for small molecules. Different functional groups are distinguishable and even identical
functional groups with differing neighboring substituents still give distinguishable signals.
As one of the most common spectroscopic techniques, NMR can uniquely identify and
simultaneously quantify a wide range of organic compounds.
NMR-based metabolomics is able to provide a ‘holistic view’ of the metabolites under
certain conditions, and thus is well-suited and advantageous for metabolomic
studies[11-17]. Compared with other techniques, NMR-based metabolomics is able to
measure intact biomaterials nondestructively and provides rich molecular structural
information as well as quantitative information of each detected metabolite. NMR also
has good reproducibility with simple sample preparation. However, the sensitivity of
NMR is relatively poor compared with MS methods, resulting in metabolites with low
abundance not detectable. In case of metabolite biomarker discovery, concentrations of
potential biomarkers may be below the detection limit of NMR and these metabolite
biomarkers will be missed[30]. Therefore, NMR is inappropriate for the analysis of large
number of low-abundance metabolites.

1.2.2.

Direct Infusion Mass Spectrometry (DI-MS)

Mass spectrometer is a molecular detector as well as a separation device. It measures the
mass-to-charge (m/z) ratio and abundance of gas-phase ions to help identify the type
and the amount

of species present in a sample[31]. Mass spectrometry has become the
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technique of choice in metabolomics because of its high sensitivity, high accuracy and
wide range of covered metabolites[32].
DI-MS directly analyzes metabolites on a high resolution, high accuracy mass
spectrometer without any previous separation. A typical analytical platform involves
coupling a chip-based nanoelectrospray ion source (nESI) with a Fourier transform ion
cyclotron resonance mass spectrometer (FTICR-MS). DI-MS has been used for
metabolomics fingerprinting, such as analysis of urine[33], plasma[34] and plant
extract[35]. DI-MS has the advantages of high sensitivity and accuracy, large dynamic
range, capable of identifying and quantifying metabolites from complex samples, no
sample cross-contamination, unchanging sample matrix and high reproducibility[36-42].
The significant drawbacks of DI-MS include severe ion suppression and low ionization
efficiencies owing to no pre-separation.

1.2.3.

Liquid Chromatography Mass Spectrometry (LC-MS)

LC-MS is currently the most widely used analytical platform in metabolomics. It allows
for the collection of both quantitative and structural information of each metabolite, and
can achieve pg mL-1 sensitivity, Therefore, LC-MS offers a very versatile tool for
metabolic study[43]. The LC-MS based metabolomics has been applied to study
serum[44,45], liver[46], lung[47] and other diseases.
The choice of LC column and mobile phase composition are the two important
components for optimization of a LC-MS system. While most of the LC-MS analyses use
reverse phase liquid chromatography (RP-LC) to separate metabolites before MS
analysis[48], hydrophobic interaction liquid chromatography (HILIC) has emerged as
another choice of separation platform for LC-MS based metabolomics[49]. HILIC is
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similar to normal phase LC, in that the stationary phase is polar; however, in contrast to
normal phase LC, the mobile phase in HILIC uses water miscible solvents, such as
acetonitrile or methanol, and also contains a substantial amount of water.
To improve the coverage of metabolites, two-dimensional liquid chromatography mass
spectrometry (2D LC-MS) has been studied. Some applications combined a HILIC
column with a reverse phase column to obtain maximum coverage of the metabolome[50].
Strong cation exchange (SCX) has also been combined with HILIC to get a better
separation for water soluble compounds[51].
Coupling LC separation with MS detection leads toimproved MS sensitivity and signal
reproducibility by reducing sample complexity, thereby alleviating matrix interferences
in the ionization process. Also good separation will result in better quality MS data due to
reduced background noise, which will significantly benefits the downstream data analysis
for metabolite identification and quantification[52-53].

1.2.4.

Gas Chromatography Mass Spectrometry (GC-MS)

In GC-MS based metabolomics, metabolites are first separated on a GC column and then
subjected to mass spectrometry. GC separates molecules based on their partition
coefficients between the mobile phase and stationary phase. The stationary phase of GC
column can be categorized as polar, semi-nonpolar and nonpolar. The mobile phase in
GC is usually He or N2. A GC column is usually coupled to a quadropole or time-of-flight
mass spectrometer equipped with a chemical ionization or electron ionization source.
GC-MS has been considered as a traditional and standard approach for metabolomics
studies because of its high separation ability, high sensitivity and easy analyte
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identification[54]. It has been widely used for metabolite profiling[55] and biomarker
discovery[56]. However, GC-MS based metabolomics requires that all metabolites must
be first derivatized and the derivatized metabolites must be volatile and thermally stable.
The added metabolite derivatization step introduces a certain level of variation to the
GC-MS analysis. For example, incomplete derivatization not only increases the sample
complexity by introducing multiple chromatographic peaks, but also makes accurate
metabolite identification and quantification challenging or even impossible.

1.3. Liver Disease
The liver is the largest internal organ and largest gland in the human body. It plays an
important role in many functions, from protein production and blood clotting to
cholesterol, glucose and iron metabolism. Liver disease is a type of damage to liver, also
called hepatic disease. Symptoms of liver diseases include weakness and fatigue, weight
loss, nausea, vomiting, and a yellow discoloration of the skin.
Fatty liver disease (FLD) occurs when fat makes up more than 5%-10% of the weight of
liver. Even though FLD is reversible, it may lead to inflammatory disease such as
steatohepatitis and eventually cirrhosis[57]. FLD can occur after drinking large amount of
alcohol(acute), or after a period of heavy drinking(chronic). Centers for Disease Control
and Prevention (CDC) defines heavy drinking as consuming 15 drinks or more per week
for men 8 drinks for women. Europe is the heaviest drinking region in the world, in terms
of the prevalence of excessive alcohol consumption, with over 20% of the European
population aged above 15 reporting heavy drinking[58]. Usally of all chronic heavey
drinkers, about 15-20% develop hepatitis or cirrhosis. Alcoholic liver disease (ALD)
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includes any hepatic manifestation of alcohol overconsumption, including fatty liver
disease, alcoholic hepatitis, and cirrhosis.
Ludwig reported a number of patients who had a liver histology characterized by fat
accumulation and the presence of hepatic inflammation, with most of the cases presenting
fibrosis in the absence of a history of excessive alcohol intake. Therefore, he coined the
term “non-alcoholic steatohepatitis”[59,60]. Non-alcoholic fatty liver disease(NAFLD) is
now the most common cause of chronic liver disease in the U.S. NAFLD consists of two
clinicopathological entities: simple steatosis and non-alcoholic steatohepatitis (NASH).
Simple steatosis usually follows a benign non-progressive clinical course. NASH may
progress to cirrhosis. These people usually have high cholesterol or triglycerides and
diabetes or prediabetes. There are about 10-20% of NASH among all NAFLD. Potential
causes of fatty liver disease include obesity, type 2 diabetes mellitus, dyslipidemia,
metabolic syndrome, medications, malnutrition, autoimmune or inherited liver disease,
rapid weight loss. NAFLD usually related to insulin resistance and the metabolic
syndrome and may also respond to treatments originally developed for other insulin
resistant states such as weight loss. So there could be a vicious cycle involving these
diseases.
Several efforts have been devoted to liver disease to discover metabolite biomarkers
using different metabolomics approaches such as GC-MS[61-63] and HPLC-MS[64-67].
The molecular mechanisms of liver disease are still not fully understood.
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1.4. Objectives of This Dissertation
The objectives of this dissertation were to develop a suite of bioanalytical platforms and
related bioinformatics tools for the study of metabolite regulation changes under different
physiological conditions, and to further apply the developed bioanalytical platforms to
discover metabolite biomarkers for various liver diseases. The remaining parts of this
dissertation are organized as follows: Chapter two introduces a bioanalytical platform of
direct infusion coupled with high resolution mass spectrometry (DI-MS) for global
metabolic profiling and its application to study polychlorinated biphenyls (PCB) effects
on non-alcoholic fatty liver disease (NAFLD). Chapter Three describes a time course
study to investigate how chronic alcohol exposure disturbs lipid homeostasis using
DI-MS based metabolomics, where in vivo metabolite deuterium labeling was employed
to analyze triacylglycerol in adipose tissue and liver tissue. Chapter Four presents a
comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry
(GCxGC-TOF MS) system and its application to study the effects of arsenic exposure in
a mouse model of diet-induced fatty liver disease. Chapter Five introduces the application
of GCxGC-TOF MS platform to study the effects of Lactobacillus rhamnosus GG on
alcoholic fatty Liver disease (AFLD) in mice.
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CHAPTER 2
METABOLOMIC ANALYSIS OF THE EFFECTS
OF POLYCHLORINATED BIPHENYLS IN
NON-ALCOHOLIC LIVER DISEASE
2.1. Introduction
The burden of liver disease has increased in the United States in parallel with the obesity
epidemic. The most common liver problems, nonalcoholic fatty liver disease (NAFLD)
or its more advanced form, non-alcoholic steatohepatitis (NASH), are thought to be due
to overweight/obesity. Polychlorinated biphenyls (PCBs) are persistent environmental
pollutants. Exposures to PCBs have been associated with NAFLD in epidemiologic
studies[68]. Among PCB congeners, PCB 153 (Figure 1) is present at the highest
levels[69]. Dr.Cave’s group has been demonstrated that chronic PCB 153 exposure
worsened obesity/NAFLD in mice fed a high fat diet (HFD), but had no pathologic effect
in mice fed control diet (CD)[70]. To better understand the biochemical mechanisms
underlying these observations, a comprehensive investigation using high throughput
analysis such as metabolomics is necessary.
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Figure 1. PCB 153 Structure

Metabolomics is the study of low molecular weight molecules (i.e., metabolites) found
within cells and biological systems.

Due to the extremely diverse chemical

characteristics of metabolites, several types of instruments have been utilized to analyze
metabolites including nuclear magnetic resonance (NMR)[13,16], liquid chromatography
mass spectrometry (LC-MS) and gas chromatography mass spectrometry (GC-MS)[22,
28,71]. Each type of instrumental analysis affords limited coverage of the metabolites,
and therefore only provides a partial metabolite profile of each sample. With the
advantages of high sensitivity and accuracy, wide dynamic range, and the ability to
identify metabolites from complex sample[39,62,72], high-resolution mass spectrometry,
such as Fourier transform ion cyclotron resonance mass spectrometer (FTICR-MS), is an
attractive option in metabolomics research[73,74].
The objective of this study was to determine if PCB 153 induces NAFLD in mice fed a
control diet and/or alters the metabolite profile, and/or exacerbates NAFLD in mice fed a
high fat diet. C57BL/6J mice were fed either a control diet (normal chow, CD) or 43%
milk fat diet (high fat diet, HFD) for 12 weeks with or without PCB 153 co-exposure. At
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the end of the feeding period, the mice were anesthetized and liver samples were
collected. The metabolite extracts from mouse livers were analyzed using linear trap
quadruple - Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FTICR
MS) via direct infusion chip-based nano-electrospray ionization (DI-nESI) – mass
spectrometry.

2.2. Experimental
2.2.1.

Animals and Diets

The animal experiment were carried out at the School of Medicine, University of
Louisville,

and the animal protocol was approved by the University of Louisville

Institutional Animal Care and Use Committee. Male C57BL/6J mice (8 weeks old, n = 40;
The Jackson Laboratory, Bar Harbor, Maine) were divided into 4 study groups (n = 10
per group) based on diet and PCB 153 exposure in this 12-week study utilizing a 2×2
design. The control diet (CD) was the Autoclavable Rodent Diet 5010 from LabDiet,
Lebanon, IN; and it consisted of 12.7% kcal from fat, 58.5% carbohydrate, and 28.7%
protein from both animal and vegetable sources. The high fat diet (HFD) was TD.88137
from Harlan Laboratories, Madison, WI; and it consisted of 42.7% kcal from fat (milk
fat), 42.0% carbohydrate (sucrose and corn starch), and 15.2% protein (casein). PCB 153
(Ultra Scientific, North Kingstown, RI) was administered in corn oil (vehicle) by i.p.
injection (vs. corn oil alone) at a dose of 50 mg/kg on weeks 4, 6, 8, and 10. Mice were
housed in a temperature- and light-controlled room (12 h light; 12 h dark) with food and
water ad libitum. The animals were euthanized (sodium pentobarbital, 40 mg/kg body
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weight, i.p.) at the end of week 12. Thus, four different treatment groups were evaluated
in this fashion: CD, CD+PCB 153, HFD, HFD+PCB 153.

2.2.2.

Liver Histological Studies

Liver sections were frozen using optimal cutting temperature (OCT), a liquid embedding
medium or fixed in 10% buffered formalin for 24 h and embedded in paraffin for
histological examinations. Tissue sections were stained with either Oil Red O (frozen
OCT), hematoxylin–eosin (H&E; formalin-fixed) or Sirius red stain (formalin-fixed) and
examined under light microscopy at 200× magnification. Photomicrographs were
captured using a Nikon Eclipse E600 Microscope.

2.2.3.

Metabolite Sample Preparation

Metabolites were extracted based on Bligh & Dyer’s method to cover both the polar and
non-polar metabolites[75]. Each sample of liver tissue was weighed and homogenized for
2 min after adding water at a concentration of 100 mg liver tissue/mL water. The
homogenized sample was then stored at –80 °C until use. To extract metabolites from the
homogenized liver tissue, 100 μL of homogenized liver tissue, 300 μL of water, and 1.5
mL of chloroform–methanol (v/v = 1:2) were mixed in a glass tube and vortexed for 1
min, followed by adding 0.5 mL chloroform, vortexing 1 min, adding 0.5 mL water and
vortexing for 1 min. The mixture was then separated by centrifuging at room temperature
for 8 min at 1100 rpm. 400 μL of the organic phase (bottom) were aspirated into another
glass tube and dried under nitrogen. Each of the dried samples was dissolved in 100 μL of
chloroform–methanol (v/v = 1:1) and further diluted 25 times before analysis. The
aqueous phase was dried in a SpeedVac at 4 oC to remove methanol, followed by freeze
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drying to vaporize water. Each of the dried water phase samples was re-dissolved in 100
μL methanol and then further diluted 5 times before analysis.

2.2.4.

Spike-in Samples

About 180 mg of liver tissue from three mice was mixed with deionized water at a
concentration of 100 mg/mL. The mixture was then homogenized for 2 min and stored at
–80 oC until use. To extract metabolites from liver, a 200 μL of homogenized liver
sample was mixed with 1.6 mL of methanol and vortexed for 1 min, followed by
centrifugation at 4 oC for 10 min at 15,000 rpm. 1.4 mL of the top solution was aspirated
into a plastic tube and dried by N2 flow. After dissolving the dried sample with 200 μL of
methanol, a stock solution was prepared by diluting the sample 10 times. Thirty aliquots
of the stock solution were then prepared with a volume of 50 μL per aliquot.
A mixture of 15 acid standards was prepared at a concentration of 10 μg/mL per acid.
The acids included L-proline, L-cystine, L-histidine, L-phenylalanine, L-tyrosine, L-lysine,
L-glutamic

acid,

L-aspartic

acid,

L-leucine,

nonadecanoic acid, hepadecanoic acid,

heptanoic acid, nonanoic acid, pentadecanoic acid, and undecanoic acid. Twenty μL of
the acid mixture was added to each of the first 10 aliquots of the stock solution, while 24
and 100 μL of the acid mixture were added to each of the second 10 aliquots and the third
10 aliquots, respectively. Methanol was then added to each of the 30 aliquots to make the
total volume of each aliquot to 200 μL. This resulted in three sample groups with
spiked-in acid standards. The acid concentration in each of the spike-in sample groups is
1.0 μg/mL, 1.2 μg/mL, and 5.0 μg/mL, respectively.
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2.2.5.

FTICR-MS and LTQ-MS/MS Analysis

The direct infusion experiments were performed on a hybrid mass spectrometer, linear
trap quadruple - Fourier transform ion cyclotron mass spectrometer (LTQ-FTICR MS or
LTQ-FT MS) (Thermo Electron Corporation, Bremen, Germany) equipped with a
chip-based nano-electrospray ionization (nESI) ion source (Triversa NanoMate) (Advion
Biosciences, Ithaca, NY, USA). The mass spectrometer was operated in positive ion
mode. Each metabolite extract was analyzed for 5 minutes with an m/z range of 50–1,600.
Mass spectra were recorded using FTICR in the profile mode and the resolving power
(RP) was set at 200,000 @ m/z = 400. The maximum ion accumulation time was set at
1,000 ms. The ion optics was tuned for the sodium adduct of tricaprylin ([C27H50O6+Na+])
at m/z = 493.25 using the linear ion trap (LIT). The two most important nESI parameters
were as follows: the spray voltage = +1.8 kV and the nitrogen gas pressure = 0.5 psi. The
MS/MS spectrum of each metabolite ion was acquired with the LTQ-MS. The parameters
were set as follows: parent ion m/z isolation window = ±0.5, spectrum accumulation time
= 1 min. The collision-induced dissociation (CID) voltage is a molecule dependent
parameter and ranged from 16 to 40 mV.

2.2.6.

Data Analysis

The FT-MS data were processed using the software package MetSign[76]. For metabolite
peak quantification, the raw instrument data were first reduced into a peak list using
second-order polynomial fitting (SPF) and Gaussian mixture model (GMM). Cross
sample alignment was performed using a two-step alignment approach implemented in
MetSign, the primary alignment and partial alignment. After peak alignment, a contrast
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based method was employed for normalization[77]. Pairwise two-tail t-test was used to
study the abundance change of each metabolite between two testing sample groups.
For metabolite identification, each peak detected in the FTICR-MS data was first
assigned to metabolite(s) recorded in the public databases (Kyoto Encyclopedia of Genes
and

Genomes

(KEGG,

(http://www.lipidmaps.org/),

http://www.genome.jp/kegg/),
and

the

Human

Metabolome

LIPID

MAPS

Database

(HMDB,

http://www.hmdb.ca/), by matching the experimentally measured metabolite ion m/z
value and the profile of the isotopic peaks with the theoretical data of database
metabolites. The thresholds for m/z variation and isotopic peak profile similarity
measured by Pearson’s correlation coefficient were set as ≤ 5 ppm and ≥ 0.75,
respectively. To narrow down the metabolite candidates of the initial assignment, the
MS/MS spectra were acquired for metabolites detected with significant abundance
changes between two testing sample groups. Each experimental MS/MS spectrum was
compared to the in silico MS/MS spectra of all candidate metabolites generated by Mass
Frontier 7.0 (Thermo Scientific, FL, US). The spectral similarity between the
experimental MS/MS spectrum and the in silico MS/MS spectrum of metabolite of
interest was evaluated using Pearson’s correlation coefficient. The metabolite candidate(s)
with the best MS/MS spectral similarity was (were) considered as the metabolite giving
rise to the experimental spectrum, while the other candidates were discarded. The
authentic standards of the metabolites of interest were then analyzed on LTQ-MS/MS to
further confirm the metabolite identification.
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To evaluate the accuracy of both the analytical platform and the data analysis method, the
true-positive rate (TPR), the positive predictive value (PPV), and their harmonic mean F1
score were calculated as follows:

TPR 

PPV 

F1 

TP
TP  FN

TP
TP  FP

(1)

(2)

2  TPR  PPV
TPR  PPV

(3)

where TP (true-positive) is the number of spiked-in acids that were detected as molecules
with significant peak area changes between groups of spike-in samples by the statistical
analysis, FP (false-positive) is the number of molecules that were not spiked-in acids but
detected as molecules with significant peak area changes, and FN (false-negative) is the
number of spiked-in acids that were not detected as molecules with significant peak area
changes. TPR is called recall, and PPV is called precision and their harmonic mean F1
score can be used as an accuracy of the statistical significant test.

2.3. Results and Discussion
2.3.1.

PCB 153 Worsened Steatosis in Mice Fed a High Fat Diet
(HFD)

Oil Red O staining is used in histological visualization of fat cells and neutral fat. Oil Red
O is a dye used for staining of neutral triglycerides and lipids on frozen sections.
Haematoxylin and eosin (H&E) staining protocol is used frequently in histology to
examin thin section of tissue. Haematoxylin stains cell nuclei blue, while eosin stains
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cytoplasm, connective tissue and other extracellular substances pink or red. Histological
examination showed that mice fed a control diet did not develop significant steatosis with
or without PCB 153 administration (Oil Red O and H&E stains-Figure 2. A&B). Mice
fed HFD showed minimal steatosis, but PCB 153 co-exposure drastically augmented this
effect. Thus, co-administration of PCB 153 to HFD–fed mice clearly worsened hepatic
steatosis while PCB 153 had no effect in the control diet fed-mice.
A

B

Figure 2.

CD

CD+PCB 153

CD

CD+PCB 153

HFD

HFD+PCB 153

HFD

HFD+PCB 153

PCB 153 worsened hepatic steatosis in mice fed a high fat diet. (A) The

HFD+PCB 153 mice showed macrovesicular steatosis by H and E staining (B) Oil Red O
staining of hepatic sections established the occurrence of micro-vesicular steatosis in the
same group of mice.

2.3.2.

Evaluation of Metabolomics Analysis Platform

The FTICR-MS data of the spiked-in experiment were processed using MetSign[75]. Of
the 15 spiked-in acids, the metabolite peaks of 10 acids (L-proline, L-cystine, L-histidine,
L-phenylalanine, L-tyrosine, L-lysine, L-glutamic

acid, L-aspartic acid, L-leucine, and

nonadecanoic acid) were recognized based on the match of m/z values and isotopic peak
profile. On the basis of the design of the spike-in experiment, all of the 10 detected
spiked-in acids are the true-positive metabolites that have different concentrations
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between the two sample groups, while all other metabolites are false-positives if they are
detected as the metabolites with significant concentration change between two sample
groups. Of the 10 detected acids,

L-histidine, L-lysine,

and nonadecanoic acid were

already present in the liver metabolite extract before the addition of the acid standards.
The true concentration ratios of these three acids between samples groups depend on the
amount of these acid originally present in the liver.
A pairwise two-tail t-test was performed to recognize the metabolite peaks with
significant peak area changes between the two testing groups constructed from the three
sample groups of the spike-in experiment. Figure 3 displays the relation between the
p-value threshold of the t-test and the recall, the precision and F1, respectively. With the
increase in the p-value threshold, the TPR increases and it reaches the highest value of
0.80 at a p-value of 0.03. There is a relatively large deviation between the PPV values of
these three pairs of testing groups. The best PPV value reaches a value of 0.63 when
comparing testing groups 1.0 μg/mL vs. 1.2 μg/mL, while it is only 0.30 for 1.0 μg/mL vs.
5.0 μg/mL and 1.2 μg/mL vs. 5.0 μg/mL at a p-value of 0.05. The F1 value ranges from
0.43 to 0.70 at a p-value of 0.05. The high value of TPR and moderate value of F1
indicate that the analytical platform and the data analysis method employed in this study
are able to detect the metabolites with abundance changes from the biological samples.
However, the analytical platform variations also introduce a certain level of false-positive
discovery, resulting moderate values of PPV and F1.
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Figure 3. Relationship between the cutoff value of the p-value of t-test and the values of TPR,
PPV, and F1 during the analysis of the spiked-in experiments. (A) TPR (B) PPV (C) F1

2.3.3.

Metabolite Identification

The metabolite putative assignment was accomplished by MetSign[75] software using the
FTICR-MS data. About 800 metabolite peaks were putatively assigned to at least one
database metabolite with an m/z variation window of ≤ 5 ppm and a minimum value of
0.75 as Pearson’s correlation coefficient between the theoretical isotopic peak profile and
the experimental one. To the metabolite peaks detected with significant abundance
changes between two testing sample groups, an experimental MS/MS spectrum was
acquired for each of these peaks on LTQ-MS/MS. An in silico MS/MS spectrum was
generated for each of the putative metabolite candidates assigned to the metabolite peaks
with significant abundance changes. The in silico MS/MS spectra were then matched to
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the experimental MS/MS spectrum of the metabolite ion. The metabolite candidate with
the best MS/MS spectral match was considered as the metabolite present in the sample.
Figure 4 depicts an example of MS/MS identification. The molecular ion m/z value of the
peak measured by FTICR-MS is 156.07731, which was tentatively assigned to the
metabolite L-histidine (a metabolite recorded in human metabolite database with database
identification number HMDB00177) with an m/z value deviation of 0.06 ppm and the
isotopic peak profile similarity of 0.9974. The in

silico MS/MS spectrum of this

putatively assigned metabolite was obtained using Mass Frontier, and the in silico
MS/MS spectrum (Figure 4A) is highly similar to the experimental spectrum (Figure 4B)
with a Pearson’s correlation coefficient of 1.00. Figure 4 shows the MS/MS spectrum of
authentic L-histidine standard. The Pearson’s correlation coefficient between the MS/MS
spectrum of the authentic L-histidine and the experimental MS/MS spectrum acquired
from the biological sample is 0.85. Such a high spectral similarity significantly increases
the identification confidence of L-histidine from the biological samples.
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Figure 4. An example of identifying metabolites using MS/MS information. The metabolite
ion m/z value was measured using FTICR-MS as 156.0773. (A) is the experiment MS/MS
spectrum of the metabolite ion. (B) is the matching result of the metabolite between the
experiment MS/MS spectrum and the in silico MS/MS spectrum of the same metabolite ion
generated by Mass Frontier 7.0. The matched fragment ions are highlighted in red and the
unmatched fragment ions in black. (C) is the MS/MS spectrum of the L-histidine standard.

2.3.4.

Metabolite Quantification

Four sample groups were generated in this study, including CD group (animals fed a
control diet), CD+PCB 153 group (animals fed a control diet with exposure to PCB 153),
HFD group (animals fed a high fat diet), and HFD+PCB 153 group (animals fed a high
fat diet with exposure to PCB 153). To investigate the metabolite abundance change
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between two sample groups, pairwise two-tail t-test was employed with a p-value
threshold of ≤ 0.05. Four pairs of sample groups were compared in this study after
normalization. Specifically, we compared the metabolite profile difference between CD
group and CD+PCB 153 group, CD group and HFD group, CD+PCB 153 group and
HFD+PCB 153 group, and HFD group and HFD+PCB 153 group.
In order to have high metabolite coverage, two samples were collected from each mouse
liver: water phase metabolite extract and organic phase metabolite extract. The statistical
test was applied to the water phase samples and the organic phase samples, respectively.
The test results were then merged for summary. A few metabolites were detected in both
the organic phase samples and the water phase samples, but none of them was recognized
as a molecule with significant abundance changes between two sample groups. For each
of the comparisons, the peak distribution of each metabolite in the samples of the two
testing sample groups was generated. Figure 5 depicts a sample peak intensity
distribution of metabolites recognized with significant abundance changes between the
HFD group and the HFD+PCB 153 group. It can be seen that the abundance of this
metabolite (fucose 1-phosphate) is significantly decreased in the HFD+PCB 153 group
with a fold-change of 2.65 and a p-value of 4.84×10-4.
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Figure 5. The peak area distribution of metabolite fucose 1-phosphate in the HFD samples
(red triangles) and in the HFD+PCB 153 samples (blue stars). The abundance test (pairwise
two-tail t-test) shows that the regulation of this metabolite in the HFD+PCB 153 group is
decreased with a fold change of 2.65 and a p-value of 4.84×10–4.

To measure the metabolite abundance changes between two sample groups, the term
fold-change was defined as the ratio of the large abundance value (peak area) of a
metabolite in one group divided by the small abundance value of the same metabolite in
the other group. The positive sign and negative sign indicate the abundance increase and
decrease in the testing group, respectively. No metabolite was detected with significant
abundance changes between the CD group and the CD+PCB 153 group. This indicates
that PCB 153 alone has no significant effect on liver at the metabolite level. However, a
total of 14 metabolites were detected with significant abundance changes between the
HFD and HFD+PCB 153 groups, as listed in Table 1. Among the metabolites with
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significant changes between the HFD and HFD+PCB 153 groups, erythronic acid
(Figure.6) had the largest abundance changes with a 28.8-fold increase in the HFD+PCB
153 group (p = 8.35×10-5). Erythronic acid is formed either by oxidation of D-N-acetyl
glucosamine, an alternating unit of hyaluronic acid [78] or by degradation of ascorbic acid
(Vitamin C) and glycated proteins[79]. Compared with the changes observed between the
CD group and CD+PCB 153 group, the metabolite abundance changes between the HFD
and HFD+PCB 153 groups demonstrated the presence of a diet-toxin interaction between
PCB 153 and HFD. This interaction may affect some metabolic pathways, and therefore
induce the abundance changes of these measured compounds. Thus, PCB 153 alone does
not induce NAFLD but it worsens NAFLD caused by a HFD, which agrees with our
histological examination (Figure 2).

Figure 6.

Erythronic Acid Structure
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Table 1.

Metabolites detected with significant abundance changes between the HFD group
and the HFD+PCB 153 group.

m/z
156.07731
170.03332

Name

Adduct
ion

Metabolite database
IDs

L -Histidine

H+

C00135,HMDB00177 -1.80

4.64E-02

+

HMDB00064,C00300 -1.83

4.72E-02

+

HMDB00613

28.77

8.35E-05

C00352

-2.19

4.14E-03

HMDB01265

-2.65

4.84E-04

HMDB04662

-2.97

1.14E-02

Creatine

K

175.00113

Erythronic acid

K

260.05434

D-Glucosamine6-phosphate

H+

262.07009

Fucose 1-phosphate

NH4
+

376.05929

S-(Hydroxymethyl)glutathione

K

346.0469

Glutathione

K+

459.25103

Stearoylglyceronephosphate

+

fold
change

p_value

HMDB00125,C00051 -5.91

2.04E-03

Na

+

C03805

-1.67

3.14E-02

+

C10944

-2.57

1.71E-02

266.153

Isobutylphendienamide

Na

309.16728

Fructoselysine

H+

C16488

-2.94

5.96E-03

347.1235

Fructoselysine

K+

C16488

283.03409

Uridine

-2.08

1.70E-02

+

HMDB00296,C00299 -1.80

4.99E-02

+

LMST01010114

-2.02

1.25E-02

LMST01100006

2.05

3.68E-03

K

559.30352

Cucurbitacin P

K

685.39477

15alpha,25-dihydroxy-16beta,23R:16alpha,24S-diepoxy9beta,19-cyclolanostan-3beta-yl
Na+
2-O-acetyl-alpha-L-arabinopyranoside

For the CD+PCB 153 vs. HFD+PCB 153 groups, 50 FTICR-MS peaks were detected
with significant abundance changes in water phase samples and 14 peaks in organic
phase samples. Combining the water phase and the organic phase results, 24 metabolites
were identified by in silico MS/MS spectral matching, although three of them (m/z =
369.1178, 203.0535 and 365.1075) do not have unique identification (Table 2). The
identified metabolites include glycerolipids, sterol lipids, phospholipids, sphingolipids
and other small molecules. It should be noted that the FTICR-MS peaks with m/z =
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309.1673 and 347.1235 were both identified as fructoselysine with different adduct ions
H+ and K+, respectively. The same fold change (-2.43) between the two testing sample
groups confirms the accuracy of our FTIRC-MS and data analysis platforms. Another
case is the identification of FTICR-MS peaks with m/z = 156.0773 and 194.0335. The in
silico MS/MS spectral matching identified these two peaks as being generated by the
metabolite L-histidine, with adduct ions H+ and K+, respectively. The fold changes of
these two FTICR-MS peaks between the two testing groups are -1.90 and -1.94,
respectively.
For the CD vs. HFD groups, 57 FTICR-MS peaks were detected having significant
abundance different between the CD group and the HFD group in the water phase
samples and 17 peaks in the organic phase samples. Combining the results of the water
phase and the organic phase samples, 25 metabolites were further confirmed by MS/MS
spectral matching. Of the 25 compounds, two do not have a unique identification (Table
3). It should be noted that metabolite PC (o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z)) has a
4.44-fold increase in the HFD group, which agrees with a previous study[80].
Several important limitations in the study design could impact the generalizability of
these results. First, differences existed between CD and HFD, not only in macronutrient
content and source, but also in micronutrient composition. However, similar, but not
identical, vitamin and mineral mixes were given with each diet. These potential
confounders could impact metabolite differences observed between diet groups
regardless of PCB administration. However, the primary study objective was to
determine the effects of PCB administration within a given diet (e.g. HFD vs. HFD+PCB
153, and CD vs. CD +PCB 153), and these analyses would be unaffected. Thus, the most
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Table 2. Metabolites detected with significant abundance changes between the CD+PCB 153
group and the HFD+PCB 153 group.

m/z

Adduct
ion
Metabolite database IDs

Metabolite Name

+

Fold
change

p_value

156.0773

L-histidine

H

C00135,HMDB00177

-1.90

1.18E-02

194.0335

L-histidine

K+

C00135,HMDB00177

-1.95

2.77E-02

227.0439

N-acetylglutamine

K+

HMDB06029

-2.17

2.23E-02

+

HMDB00613

16.73

2.90E-04

+

175.0011

Erythronic acid

K

219.0274

2S,4S,5R,6-tetrahydroxy-hexanoic acid

K

LMFA01050392

-2.81

1.64E-03

249.0383

Chorismate

Na+

260.0543

D-glucosamine6-phosphate

HMDB12199

-2.38

3.39E-03

+

C00352

-1.84

4.85E-02

+

H

268.1054

Adenosine

H

HMDB00050

-1.64

2.76E-02

286.2757

heptadecasphing-4-enine

H+

347.1235

Fructoselysine

LMSP01040002

3.29

5.64E-03

+

C16488

-2.43

3.62E-02

+

4.25E-02

K

309.1673

Fructoselysine

H

C16488

-2.43

346.0469

Glutathione

K+

C00051,HMDB00125

-19.86 9.13E-03

376.0593

S-(hydroxymethyl)glutathione

K+

HMDB04662

-3.67

5.56E-04

HMDB00048

-3.79

8.55E-04

C03451,HMDB01066

-3.51

9.51E-04

LMST01010114,C08804

-1.87

1.87E-02

HMDB13451

2.45

1.20E-03

LMGL02010021

-2.37

6.24E-04

381.0813

+

Melibiose

K

402.0964

S-lactoylglutathione

Na

559.3035

Cucurbitacin P

K+

867.6961

PC(o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z))

+

NH4
Na

+

+

615.4948

1,2-di-(9Z-heptadecenoyl)-sn-glycerol

685.3948

15alpha,25-dihydroxy-16beta,23R:16alpha,24S-diepoxy-9be
ta,19-cyclolanostan-3beta-yl
Na+
2-O-acetyl-alpha-L-arabinopyranoside

LMST01100006

2.25

5.01E-04

903.7553

1-docosanoyl-2-(15Z-tetracosenoyl)-sn-glycero-3-phosphoet
NH4+
hanolamine

LMGP02010292

8.09

1.13E-03

899.7505

1-heptadecanoyl-2-(9Z-heptadecenoyl)-3-octadecanoyl-sn-gl +
K
ycerol

LMGL03010071

5.86

1.44E-05

369.1178

O-feruloylquinate

C02572

-3.29

2.01E-02

-2.22

5.73E-03

-5.86

5.38E-05

Na+
Na

+

C09771,LMPR0102070006

D-glucose

Na

+

C00031

2S,4S,5R,6-tetrahydroxy-hexanoic acid

Na+

Aucubin
203.0535

365.1075

Melibiose
Sucrose
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LMFA01050392

Na

+

C05402,HMDB00048

Na

+

C00089

Table 3. Metabolites detected with significant abundance changes between the CD group and
the HFD group.

m/z

Adduct
ion
Metabolite database IDs

Metabolite Name

+

Fold
Change

p_value

175.0011

Erythronic acid

K

HMDB00613

-26.70

4.16E-02

219.0274

2S,4S,5R,6-tetrahydroxy-hexanoic acid

K+

LMFA01050392

-1.72

1.21E-02

251.054

2-Hydroxy-3-carboxy-6-oxo-7-methylocta-2,4-dienoate

Na+

C06581

-2.25

4.58E-03

HMDB01265

1.93

5.55E-03

LMSP01040002

3.92

1.74E-03

262.0701

+

Fucose 1-phosphate

NH4
+

286.2757

heptadecasphing-4-enine

H

355.0671

2-Caffeoylisocitrate

H+

364.1238

Lactosamine

C02927

-1.92

4.54E-02

Na

+

HMDB06591

1.77

9.17E-03

+

C01121

-1.80

6.33E-03

365.0966

Streptidine6-phosphate

Na

365.102

Hinokitiolglucoside

K+

380.0977

Lactosamine

C15451

-3.93

3.16E-04

+

HMDB06591

1.36

4.94E-02

+

K

381.069

Streptidine6-phosphate

K

C01121

-2.36

1.41E-03

384.1218

Acutumidine

H+

C10565

-1.87

1.26E-02

390.3365

N-(5-hydroxy-pentyl)-5Z,8Z,11Z,14Z-eicosatetraenoyl
amine

H+

LMFA08020020

-4.94

3.06E-02

399.0858

Elephantopin

K+

LMPR0103090004,C09403 -2.55

5.92E-03

459.251

Stearoylglyceronephosphate

Na+

C03805

2.10

1.33E-03

+

C11050

2.05

4.42E-02

C11050

1.96

7.21E-03

HMDB02094

-2.53

1.15E-02

C11050

1.64

2.11E-02

LMGL02010021

-3.66

3.02E-02

497.3475

25-Hydroxy-24-epi-brassinolide

H

519.3296

25-Hydroxy-24-epi-brassinolide

Na

527.1377

3-Fucosyllactose

K+

535.3036

+

+

25-Hydroxy-24-epi-brassinolide

K

+

615.4948

1,2-di-(9Z-heptadecenoyl)-sn-glycerol

Na

663.0984

Isoorientin 3'-O-glucuronide

K+

LMPK12110311

-5.87

6.50E-04

867.6961

PC(o-22:1(13Z)/20:4(8Z,11Z,14Z,17Z))

NH4+

HMDB13451

4.44

5.25E-05

879.6859

1-heptadecanoyl-2,3-di-(9Z,12Z-heptadecadienoyl)-sn-glyce +
K
rol

LMGL03010067

28.39

1.34E-05

203.0535

2S,4S,5R,6-tetrahydroxy-hexanoic acid

LMFA01050392

-1.47

2.23E-02

-3.18

1.49E-04

Na+
Na

+

C00031

Melibiose

Na

+

C05402,HMDB00048

Sucrose

Na+

D-Glucose
365.1075
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C00089

important conclusion from our work is that macronutrient-toxicant interactions are
critical determinants of PCB 153’s effects on hepatic metabolites. Additional
consideration must also be given to the PCB dosing protocol. PCBs were manufactured
as mixtures, and multiple highly chlorinated PCB congeners have simultaneously
bio-accumulated in humans primarily by ingestion[68]. This study investigated only a
single congener (PCB 153), which is the single most abundant PCB in humans[1].
Because a metabolomics dose response curve has never been performed for any PCB, for
this initial study a relatively high cumulative dose (200 mg/kg, administered to mice i.p.,
over 12 weeks) was selected based on a previously published National Toxicology
Program Protocol (NTP TR 530, 210 mg/kg cumulative dose, administered to rats by
gavage over 14-weeks. The NTP protocol produced lipid-adjusted serum PCB levels
approximately 10-fold higher than the most highly exposed subject from the Anniston,
Alabama human cohort of highly-exposed residents living near a former PCB production
facility[81]. Limitations regarding our PCB dosing protocol must be acknowledged and
future studies investigating PCB mixtures at lower doses and more physiologic routes of
administration (e.g. gavage) have been planned. However, the most important finding of
this study is that even at a relatively high dose of PCB 153, no effects on hepatic
metabolites were observed in the absence of high fat feeding. Therefore, the data suggest
that the PCB-HFD interaction could be more important than the cumulative PCB dose.

2.3.5.

Ingenuity Pathway Analysis (IPA)

As demonstrated by the spike-in experimental data, the analytical platform and the data
analysis method employed in this study can introduce a certain level of technical
variations. Such variations can cause both false-positive and false-negative discoveries.
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On the other hand, the quantitative analysis was performed on the abundance of each
individual metabolite. The inter-relationships between the various metabolites were not
considered however, and thus, IPA was employed. IPA correlates specifically targeted
metabolites with potential metabolic pathways for data analysis that helps researchers to
model, analyze, and understand complex biological and chemical systems at the core of
life science research[82]. Therefore, it is necessary to incorporate the analytical discovery
with the metabolite pathway analysis to further filter and/or enrich the analytical
discovery.
All 14 metabolites recognized with significant abundance changes between the HFD
group and the HFD+PCB 153 group were subjected to IPA for network analysis. Six
metabolites were mapped into the IPA database. The most probable metabolite network
reported by IPA contained 5 metabolites including creatine, glucosamine-6-phosphate,
glutathione, L-histidine and uridine with a score of 14 (Figure 7). The IPA analysis
resulted in that the top hepatotoxicity function is glutathione (GSH) depletion in liver and
the top canonical pathway is glutamate metabolism. GSH, a tripeptide composed of
glutamic acid, cysteine and glycine, is the major intracellular anti-oxidant in the liver, and
its physiological function is to prevent damage to cellular components that may be caused
by xenobiotic metabolites, reactive oxygen species (ROS) and free radicals[83]. In the
liver, glutamate is the terminus for release of ammonia from amino acids, and the
intrahepatic concentration of glutamate modulates the rate of ammonia detoxification into
urea[83,84].
GSH (entry 7 of Table 1) had a 5.91-fold decrease in the HFD+PCB 153 group (p-value
of 2.03×10-3) and its conjugate, S-(hydroxymethyl)glutathione (entry 6) had a 2.97-fold
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decrease (p-value of 1.14×10-2).

Hepatic mitochondrial GSH depletion has been

associated with the progression of alcoholic liver disease[85] and blood GSH depletion
with obesity and diabetes[86]. Lower hepatic GSH content has also been reported in
non-alcoholic steatosis[87]. Furthermore, Swenberg et al. reported the formation of
oxidative DNA lesions in PCB 126-exposed rats which was likely due to ROS
generation[88]. Therefore, the GSH depletion noted in the steatotic livers of mice treated
with HFD+PCB 153 implies increased oxidative stress leading to extensive utilization of
GSH which eventually decreased liver GSH stores. Further evidence for oxidative stress
can also be accounted for by the increased levels of erythronic acid, the degradation
product of vitamin C, another crucial anti-oxidant. The mechanism by which PCB 153
induces oxidative stress needs further investigation. PCB 153 is very poorly
metabolized[89] and therefore conjugation of its metabolites is very unlikely to deplete
glutathione.
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Figure 7. IPA proof-of-knowledge characterization of the metabolic networks in mouse liver
affected by PCB 153.The dashed line indicates indirect interactions between metabolites
while the solid line means a direct metabolite interaction. Filled circles represent metabolites
discovered in this work and the color of each filled circle represents the direction and
magnitude of fold-changes. Green color means down-regulated, red color means
up-regulated.
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Unlike PCB 126, which is a potent Ah-receptor agonist strongly inducing CYP1A
activity, PCB 153 is reported to have weak “Phenobarbital” activity[90] suggesting it will
be a relatively poor inducer of CYP2B and thus is expected to have relatively poor ability
to induce monooxygenase activity which could increase the levels of reactive compounds
that reduce glutathione levels. However, it is possible that the depletion could be due to
glutathione consumption by increased lipid peroxides which should have been generated
within the steatotic livers of the HFD+PCB 153 group. It must also be noted that our
results are consistent with the findings of Twaroski et al., as we observed no effects of
PCB 153 on glutathione in the presence of a normal rodent chow diet[91]. PCB
153-mediated glutathione depletion occurring only in the presence of HFD is not only
innovative, but also probably the most important finding in this study.
Regardless of its mechanism, the reduction in glutathione (entry 7 of Table 1) would
diminish its availability for transformation into S-(hydroxymethyl)glutathione (entry 6),
and should trigger the up-regulation of glutathione biosynthesis from glutamate, glycine,
and cysteine, its component amino acids. Glutamate is made from the TCA cycle
intermediate 2-oxoglutarate and ammonia, which could account for the decrease in
measured D-glucosamine 6-phosphate (entry 4), either from its use as an ammonia source
or from lowered production due to ammonia depletion. Histidine (entry 1) can also be
rationalized as an ammonia source by decarboxylation and oxidation or as a source of
both ammonia and glutamate via the pathway initiated by the action of histidine
ammonia-lyase. The synthesis of uridine (entry 12) likely falls as ammonia is shunted
into glutamate production. The degradation of creatine (entry 2) gives rise to glycine
through the action of creatinase and sarcosine dehydrogenase. Interestingly, reduced
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serum creatine levels in humans and mouse models has recently been reported in a
metabolomic profiling studies of steatosis[92] and NAFLD progression[93]. Such a
simple accounting of glutathione consumption upon exposure of the liver to PCB 153,
therefore, provides good rationalization of the observed reduction in metabolite levels
(Table 1), centered on the glutamate metabolism.
IPA mapped 7 of the 24 metabolites recognized with significant abundance changes
between the CD+PCB 153 group and HFD+PCB 153 group. The most probable
metabolite network reported by IPA contained 6 metabolites including adenosine,
L-histidine, glutathione, D-glucose, melibiose and S-lactoylglutathione with a score of 16.
The top hepatotoxicity function is glutathione depletion in liver and the top canonical
pathway is also glutamate metabolism. D-glucose was detected with a 2.22-fold decrease
in the HFD+PCB 153 group, indicating a significant decrease of D-glucose in the liver
due to the exposure to PCB 153. D-glucose has been used as a biomarker for diagnosis of
liver cancer[35]. GSH was detected with a 19.9-fold decrease in the HFD+PCB 153
group, and this provides further evidence in the importance of HFD in PCB 153-mediated
GSH depletion.
Seven of the 25 metabolites with significant abundance changes between the CD group
and HFD group were mapped to the IPA database. The most probable metabolite network
reported by IPA has a score of 11 and contains 5 metabolites including
stearoylglyceronephosphate, fucose 1-phosphate, melibiose, streptidine 6-phosphate, and
2-Hydroxy-3-carboxy-6-oxo-7-methylocta-2,4-dienoate.
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2.4.

Conclusions

Polychlorinated biphenyls (PCBs) are persistent environmental pollutants. The hepatic
effects of PCB 153 in mice were investigated via a direct infusion nano-electrospray
ionization linear trap quadrupole - Fourier transform ion cyclotron resonance mass
spectrometry (DI-nESI-LTQ-FTICR MS). No difference was observed in the metabolite
profile of mice a fed control diet with or without PCB 153 exposure. However, when
mice fed a high fat diet were compared with mice fed a control diet, 15 metabolites were
reduced and 10 metabolites were increased. Compared to the CD+PCB 153 group, 18
metabolites were reduced while 6 metabolites were increased in the HFD+PCB 153
group. Compared with the HFD group, 12 metabolites were reduced including
glutathione and creatine and 2 metabolites were increased, most notably erythronic acid,
in the HFD+PCB 153 group. These data indicate that PCB 153 had no observable effects
on metabolites when administered to mice fed CD, which is consistent with the absence
of histopathology. In contrast, when administered with HFD, PCB 153 produced
significant metabolic changes (vs. HFD, or CD+PCB 153), which are consistent with
worsened obesity/NAFLD pathology. Thus, the metabolic effects of PCB 153 were
heavily dependent on macronutrient interactions with HFD. Antioxidant depletion is
likely to be an important consequence of this interaction, as this mechanism has
previously been implicated in obesity/NAFLD.
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CHAPTER 3
CHRONIC ALCOHOL EXPOSURE DISTURBS
LIPID HOMEOSTASIS AT THE ADIPOSE-LIVER
AXIS: ANALYSIS OF TRIACYLGLYCEROLS
USING HIGH-RESOLUTION MASS
SPECTROMETRY IN COMBINATION WITH IN
VIVO METABOLITE DEUTERIUM LABELING
3.1. Introduction
It has been understood that dietary fats are digested in the intestinal epithelial cells, and
then converted to triacylglycerols (TGs). TGs are assembled with apolipoproteins to form
chylomicrons which are transported into the blood stream via the lymph system[94]. TGs
are also synthesized by the liver where they are packaged as very low-density
lipoproteins (VLDL) and secreted into the blood[94]. Upon arrival in the adipose and
muscle tissues, lipoprotein lipase cleaves TG into free fatty acids and glycerol. Fatty
acids are taken up by these tissues, and are used as energy sources via oxidation in
muscles, or re-assembled into TGs to store excess energy in the white adipose tissue
(WAT)[95]. Glycerol is transported to liver or kidneys where it is converted into
dihydroxyacetone phosphate by glycerol kinase and glycerol-3-phosphate dehydrogenase.
WAT plays an important role in regulation of whole body energy homeostasis. WAT
stores excess energy in the form of TG under positive energy balance condition, and
releases fatty acids for energy generation under negative energy balance condition[95].
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However, excess fatty acid release from the WAT may cause fatty acid overflux into the
liver, leading to development of fatty liver[96]. Fatty liver is frequently associated with
both alcohol abuse (alcoholic fatty liver, AFL) and obesity (nonalcoholic fatty liver,
NAFL). Although previous studies have demonstrated similarities and differences in the
pathogenesis of fatty liver between alcohol abuse and obesity, increased fatty acid uptake
has been suggested to be a common mechanism for AFL and NAFL[97,98]. While
hepatocytes isolated from both alcohol-fed and obese rats showed an increased fatty acid
uptake[99], further investigation is needed to provide direct evidence that fatty acids
released from the WAT are indeed deposited in the liver.
Clinical studies have demonstrated that lower fat mass (lipodystrophy) was associated
with higher liver fat in alcoholics[100,101]. Animal models of AFL also showed that
reduction of WAT mass was associated with an increased fatty acid uptake by
hepatocytes[102-104]. Our study demonstrated that alcohol exposure to mice caused
more hepatic accumulation of TGs which were labeled before alcohol exposure[105]. We
also found that alcohol exposure stimulated adipose lipolysis and fatty acid release from
WAT[105,106]. These data suggest that alcohol exposure may cause an excess reverse
fatty acid transport, thereby inducing fatty liver. Therefore, the animal model of AFL
could be an ideal model to identify the importance of WAT in maintaining lipid
homeostasis at the WAT-liver axis. Further determination of triacylglycerol homeostasis
at the WAT-liver axis could reveal the direct link between WAT and liver, an
organ-organ interaction mechanism, in the development of fatty liver.
The objective of this work was to use high-resolution mass spectrometry in combination
with metabolite deuterium labeling to test our hypothesis that alcohol exposure disturbs
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lipid homeostasis at the WAT-liver axis towards triacylglycerol epitomic deposition in
the liver. In order to differentiate the liver lipids synthesized using fatty acids from other
sources from that synthesized using the fatty acids transported back from adipose tissue, a
two-stage feeding experiment was performed, where all mice were first fed with
deuterated water (2H2O) to ensure that the lipids stored in adipose tissue are deuterium
labeled (stage one). The mice were then randomly grouped into two cohorts, the control
cohort and the test cohort. Mice in the test cohort were fed an alcohol-containing liquid
diet while mice in the control cohort were pair-fed an isocaloric maltose dextrin control
liquid diet. The mice in both the control and test cohorts were then sacrificed at different
times (stage two). Metabolite extracts from mouse liver, epididymal white adipose tissue
(eWAT) and subcutaneous white adipose tissue (sWAT) were analyzed using linear trap
quadrupole–Fourier transform ion cyclotron resonance mass spectrometer (LTQ-FTICR
MS) via direct infusion electrospray ionization–mass spectrometry.

3.2. Experimental
3.2.1.

Animals and Treatments

Male C57BL/6N mice were obtained from Harlan (Indianapolis, IN, USA). All the mice
were treated according to the experimental procedures approved by the University of
Louisville Animal Care and Use Committee. To label lipids in adipose tissues, an
approach using 2H2O as the metabolic tracer was followed[107]. Mice at two months old
were given an initial priming dose of 99.8% 2H2O via an intraperitoneal injection to
achieve 2.5% of body water enrichment, followed by administration of 5% 2H2O in the
drinking water for five weeks (stage one, time point 0 week). The mice were then
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randomly grouped into two cohorts, the control cohort and the test cohort, for a 4-week of
alcohol exposure (stage two). The test cohort was fed a modified Lieber-DeCarli alcohol
liquid diet which contained 1,000 kcal/L calories, 34% from alcohol, 18% from protein,
34% from fat, and 14% from carbohydrate. The control cohort was fed a modified
Lieber-DeCarli control liquid diet which also contained 1,000 kcal/L calories with
replacement of the alcohol calories by isocaloric maltose dextrin. The alcohol-fed mice
were free access to the alcohol diet, while the pair-fed mice were given the control diet in
the same amount consumed by alcohol-fed mice in the previous day. The liquid diet
feeding was conducted for 2 (time point of two weeks) or 4 (time point of four weeks)
weeks. At the end of each feeding time point, mice were anesthetized, and liver, eWAT
and sWAT tissues were collected from each mouse for measuring lipid components
labeled by deuterium. There were 5, 5, 3 and 5, 7, 5 mice at time point 0, 2, 4 weeks for
the control cohort and the test cohort, respectively.

3.2.2.

Tissue Sample Preparation

Liver, eWAT and sWAT samples were weighed, homogenized for 2 min and stored at
–80 °C until use. To extract metabolites from the homogenized tissue, 100 μL of
homogenized tissue sample, 20 μL of butylatedhydroxytoluene (BHT) mixture (50 mg
BHT into 1 mL methanol) and 2.0 mL chloroform–methanol (v/v = 2:1) were mixed and
vortexed for 2 min followed by adding 420 μL of water and vortexing for 2 min. The
mixture was then centrifuged at room temperature at 2,000 rpm for 8 min. 400 μL of the
organic phase (bottom) was aspirated into another glass tube and dried using a nitrogen
evaporator. The dried sample was then dissolved into 200 μL of chloroform–methanol
(v/v = 2:1).
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3.2.3.

FT-MS and LTQ-MS/MS Analysis

The direct infusion experiments were performed on a hybrid mass spectrometer, the
so-called linear trap quadrupole – Fourier transform ion cyclotron resonance mass
spectrometer (LTQ-FTICR MS or LTQ-FT MS) (Thermo Electron Corporation, Bremen,
Germany) equipped with a chip-based nano-electrospray ionization (nESI) ion source
(TriversaNanoMate) (Advion Biosciences, Ithaca, NY, USA). The mass spectrometer
was operated in the positive ion mode. Each metabolite extract was measured for 5 min
covering the m/z = 100-1,600 range. The mass spectra were recorded using the FTICR in
profile mode and the resolving power (RP) was set at 400,000 @ m/z = 400. The
maximum ion accumulation time was set at 1,000 ms. The ion optics was tuned for the
sodium adduct of tricaprylin ([C27H50O6+Na+]) at m/z = 493.25 using the linear ion trap
(LIT). The two most important nESI parameters were as follows: the spray voltage =
+1.8 kV and the nitrogen gas pressure = 0.5 psi. The MS/MS spectrum of each metabolite
ion was acquired on the LTQ. The parameters were set as follows: precursor ion m/z
isolation window = ±0.3, spectrum accumulation time = 1 min. The normalized collision
energy (NCE) is a molecule dependent parameter and ranged from 16 to 40%.

3.2.4.

Metabolite Quantification

The experimental data were processed using software package MetSign[108]. After peak
alignment, a contrast based method was employed for normalization[76,77]. Both the
Fisher’s exact test and the pairwise two-tail t-test were used to study the concentration
change of each metabolite between the two physiological conditions. The parameters
used during the analysis are as follows: precursor ion m/z accuracy ≤ 5 ppm and the
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q-value for false discovery rate (FDR) ≤ 0.2[109]. Temporal analysis as performed to
study the correlation between time course trajectories measured by Pearson’s correlation
coefficient and the distance measured by Fisher’s combined probability test[110,111].

3.2.5.

Metabolite Identification

Metabolite identification was achieved in two sequential steps, database search and
MS/MS characterization. Such a metabolite identification process meets the requirement
of Level 2 metabolite identification, i.e., putatively annotated metabolites[112]. The
metabolite database search was accomplished by the MetSign software using the
FTICR-MS data. Each of the measured metabolite ion m/z value and isotopic peak profile
were compared to the corresponding theoretical information of metabolites recorded in
the MetSign database, which was composed of all metabolites recorded in the Kyoto
Encyclopedia of Genes and Genomes, LIPID MAPS, and the Human Metabolome
Database, resulting in 43,245 records. Possible positive-mode adduct ions include H+,
Na+, K+, and NH4+.
To narrow down the metabolite candidates generated by database searching, the MS/MS
spectra of metabolite peaks with significant concentration changes between two sample
cohorts were acquired on LTQ-MS/MS. Each experimental MS/MS spectrum was
compared to the in silico MS/MS spectra of all metabolite candidates using Mass Frontier
6.0 (Thermo Scientific, FL, USA). The spectral similarity between the experimental
MS/MS spectrum and the in silico MS/MS spectrum of the metabolite of interest was
evaluated using Pearson’s correlation coefficient. The metabolite candidate(s) with the
best MS/MS spectrum match was (were) considered as the metabolite giving rise to the
experimental spectrum.
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3.2.6.

Measurements of Liver Steatosis and Routine Parameters

Neutral lipids in the liver were detected by Oil red O staining. Liver cryostat sections
were cut at 7 μM, fixed with 10% formalin for 5 min, and stained with Oil red O in
2-propynal solution for 10 min. Plasma alanine aminotransferase (ALT) activity and
triglyceride and cholesterol concentrations were determined using Infinity Reagents
(Thermo Scientific, Middletown, VA). Plasma free fatty acids (FFA) were quantified
using a FFA Quantification Kit (BioVision, San Francisco, CA). Statistical differences
were analyzed by one-way ANOVA followed by Bonferroni post hoc comparison. The
data are presented as mean ± SD and p values less than 0.05 were considered as
significant.

3.3. Results
3.3.1.

Metabolite Identification

The metabolite initial assignment via database search was achieved using high-resolution
FTICR-MS data. Figure 8 is a sample of putative identification of triacylglycerol
TG(16:0/18:2/20:4)[iso6]. The m/z value of this metabolite was measured as 904.7407 by
FTICR-MS. By searching the 43,245 database metabolites, this metabolite ion and its
isotopic peak profile match the corresponding theoretical information of metabolites
HMDB05391, HMDB10508, and HMDB13423 with adducts of Na+, H+ and K+,
respectively. The number of deuterium atoms incorporated in these three metabolite
candidates is 3, 5, and 6, respectively. Therefore, the m/z values of the corresponding
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Figure 8. An example of identifying a deuterium incorporated metabolite using MS/MS
information.The metabolite ion m/z value was measured on FTICR-MS as 904.74066. (A) is
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the experimental MS/MS spectrum of non-deuterated metabolite. (B) is the matching result
of the non-deuterated metabolite between the experiment MS/MS spectrum and the
theoretical MS/MS spectrum generated by Mass Frontier. The matched fragment ions are
highlighted in red and the not matched ions in black. (C) is the MS/MS spectrum of
deuterium incorporated metabolite.

non-deuterium incorporated metabolites of these three metabolite candidates should be
901.7407, 899.7407 and 898.7407, respectively. In order to confirm the initial assignment,
LTQ-MS/MS experiments were performed to acquire MS/MS spectra for each of these
metabolite ions. Figure 8A is the LTQ-MS/MS spectrum of the metabolite ion with a
measured m/z = 901.57. The molecular structures of the candidate metabolites
HMDB05391, HMDB10508, and HMDB13423 were then uploaded into Mass Frontier
with corresponding adducts Na+, H+ and K+, respectively, to generate in silico MS/MS
spectra for each of these three candidates. Each of the in silico spectra was then matched
to the experimental LTQ-MS/MS spectrum. The in silico MS/MS spectrum of metabolite
HMDB05391+Na+ has the best match with a Pearson’s correlation coefficient of
0.9981 and therefore, this metabolite was considered as the metabolite present in the
sample (Figure 8B).
It should be pointed out that Mass Frontier software can only predict the m/z values of
fragment ions, but not the fragment ion abundance. It then matches the m/z values of the
predicted fragment ions to the m/z values of experiment mass spectrum. Therefore, a high
value of Pearson’s correlation coefficient only refers to the matching quality of fragment
ion m/z values between an in silico MS/MS and an experiment MS/MS spectrum.
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The incorporated deuterium atoms in a metabolite do not significantly affect the
metabolite fragmentation during MS/MS analysis, resulting in similar MS/MS spectra
between the deuterium incorporated metabolite and the corresponding non-deuterium
incorporated metabolite. The only difference between the MS/MS spectra is m/z values
of the fragment ions that carry deuterium atoms. The difference in the m/z values
between the corresponding fragment ions in the two spectra may range from zero to the
mass of all incorporated deuterium atoms. Figure 8C is the LTQ-MS/MS spectrum of a
deuterium incorporated version of metabolite HMDB05391 with a measured metabolite
ion m/z = 904.80. The corresponding fragment ions between the deuterium incorporated
fragment ions and the non-deuterium incorporated fragment ions are (904.80, 901.57),
(887.99, 883.62), (648.45, 645.39), (624.40, 621.37), (622.39, 619.44), (602.45, 599.44)
and (600.46, 597.47). The number of incorporated deuterium atoms in each fragment ion
is 3, 3, 3, 3, 3, 3 and 3, respectively. The spectral similarity between the spectrum of a
deuterium incorporated metabolite (Figure 8C) and the spectrum of the corresponding
non-deuterium incorporated metabolite (Figure 8A) was evaluated using Pearson’s
correlation coefficient, after recognizing the pairs of fragment ions between the spectrum
of a deuterium incorporated metabolite and the spectrum of a non-deuterium incorporated
metabolite. The Pearson’s correlation coefficient between the top 10 abundant fragment
ions in the two spectra displayed in Figures 8A and 8C is 0.8744, showing the high
similarity between these two spectra.
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3.3.2.

Statistical Significance Tests

Figure 9 depicts peak area distribution of triacylglycerol TG(16:0/18:2/20:4)[iso6] at time
two weeks among the samples of the test and control cohorts. It can be seen that this
molecule is significantly increased with a 2.8-fold change in the test cohort compared to
its level in the control cohort. The fold change was defined as the ratio of the average
peak area of a metabolite measured in the test cohort divided by the average peak area of
the same metabolite in the control cohort. The p-value of the pairwise two-tail t-test is
1.4×10-5.
4

x 10
3

Intensity

2.5
2
1.5
1

LIV_Control
LIV_Test

lC

_7

_6

_8
lC

lC

lC

lC

_1
0

0

_9
lT
_2
3
lT
_2
4
lT
_2
5
lT
_2
6
lT
_2
7
lT
_2
8
lT
_2
9
lT
_3
0

0.5

Sample ID

Figure 9. Sample concentration changes of metabolite in two different physiological
conditions.The abundance test (pair-wise two-tail t-test) shows that the concentration of this
metabolite in the test cohort is increased with a fold change of 2.8 and a p-value of 1.4×10-5.
This metabolite was further identified as TG(16:0/18:2/20:4)[iso6] by MS/MS analysis.
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Table 4 lists all of the metabolites identified with significant concentration changes in
liver between the control cohort and the test cohort at two and four weeks. All of these
metabolites were identified as deuterium incorporated TGs even though all the 43,245
metabolites were searched for the metabolite identification. Secondly, the deuterium
incorporated TGs, 13 at 2 weeks and 10 at 4 weeks, were all increased in the test cohort
with a 1.7 to 6.3-fold change. Tables 5 list all of the metabolites identified with
significant concentration changes between the control cohort and the test cohort at two
and four weeks in the eWAT and sWAT. These metabolites are all deuterium labeled and
identified as TGs. The number of deuterated TGs was more in the eWAT (10 TGs)
compared to the sWAT (4 TGs). All these deuteraed TGs were reduced by alcohol
exposure at either two weeks or four weeks with a fold-change ranged from 0.19 to 0.77.
Table 4. List of triacylglycerols in liver identified with significant concentration changes
between the control cohort and the test cohort at two and four weeks.
Time
m/z

p-value

Fold change
(T/C)a

Metabolite common name

Adduct
ion

No. 2H

2

878.7338

7.8×10-3

2.1

TG(16:1/18:2/20:4)[iso6]

H+

1

2

902.7352

1.0×10-4

8.1

TG(16:0/18:2/20:4)[iso6]

Na+

1

2

904.7407

1.4×10-5

2.8

TG(16:0/18:2/20:4)[iso6]

Na+

3

2

907.7698

2.8×10-3

2.8

TG(16:0/18:0/20:4)[iso6]

Na+

4

TG(16:0/20:4/20:4)[iso3]

H+

4

TG(16:0/20:4/20:4)[iso3]

Na+

1

TG(18:3/18:2/22:6)[iso6]

H+

1

(Week)

2

926.7360

6.9×10-3

4.2

2

927.7376

2.3×10-3

1.9

TG(16:0/20:4/20:4)[iso3]

Na+

2

2

928.7407

5.7×10-3

1.9

TG(16:0/20:4/20:4)[iso3]

Na+

3

2

929.7534

1.6×10-2

1.7

TG(16:0/20:4/20:4)[iso3]

Na+

4

TG(18:3/18:2/22:6)[iso6]

H+

4

TG(18:3/18:3/20:0)[iso3]

Na+

1

2

930.7666

3.1×10-2

3.1
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2

952.7521

8.6×10-3

6.3

TG(18:1/20:4/20:4)[iso3]

Na+

1

TG(18:3/20:4/22:6)[iso6]

H+

3

2

954.7666

9.1×10-3

3.0

TG(20:4/18:1/22:6)[iso6]

H+

1

2

903.7797

7.2×10-3

na b

TG(16:0/18:0/18:0)[iso3]

K+

2

2

905.7533

4.8×10-3

nab

TG(16:0/18:2/20:4)[iso6]

Na+

4

TG(16:0/20:4/20:4)[iso3]

H+

2

4

902.7352

2.1×10-3

3.8

TG(16:0/18:2/20:4)[iso6]

Na+

1

4

904.7407

4.4×10-2

1.7

TG(16:0/18:2/20:4)[iso6]

Na+

3

4

926.7360

1.8×10-3

2.7

TG(16:0/20:4/20:4)[iso3]

Na+

1

TG(18:3/18:2/22:6)[iso6]

H+

1

4

927.7376

3.8×10-3

2.5

TG(16:0/20:4/20:4)[iso3]

Na+

2

4

928.7407

3.6×10-2

1.7

TG(16:0/20:4/20:4)[iso3]

Na+

3

4

929.7534

2.2×10-2

1.9

TG(16:0/20:4/20:4)[iso3]

Na+

4

TG(18:3/18:2/22:6)[iso6]

H+

4

4

930.7666

3.2×10-2

2.8

TG(18:3/18:3/20:0)[iso3]

Na+

1

4

952.7521

2.8×10-2

3.6

TG(18:1/20:4/20:4)[iso3]

Na+

1

TG(18:3/20:4/22:6)[iso6]

H+

3

4

953.7545

2.5×10-2

2.7

TG(18:3/20:4/22:6)[iso6]

H+

4

4

954.7666

5.3×10-3

3.3

TG(20:4/18:1/22:6)[iso6]

H+

1

a. Fold-change is the ratio of average peak area of a metabolite in the test cohort (T) to
that in the control cohort (C).
b. na refers to a metabolite that was detected only in the test cohort. Therefore, the values
of fold change for these metabolites are not available.

3.3.3.

Temporal Analysis

Even though the statistical significance tests support the hypothesis of reverse fatty acid
transport, it is still necessary to investigate the trajectory of each metabolite in the time
course. Figure 10 shows three sample time course trajectories in liver, eWAT and sWAT,
respectively. Figure 10A displays the time course trajectory of triacylglycerol
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TG(16:0/18:2/20:4)[iso6] with one 2H label and one Na+ as adduct ion in liver samples.
While this TG molecule was not significantly increased in control cohort, it was
significantly increased in test cohort at 2 weeks and a further elevation was found at 4
weeks.

Figures

10B

and

10C

show

the

time

course

trajectories

of

TG(16:0/16:1/16:1)[iso3] with one 2H label and an adduct ion of Na+ in eWAT samples,
TG(16:0/16:0/18:1)[iso3] with one 2H label and an adduct ion of Na+ in sWAT samples,
respectively. In contrast to the increase in the liver of test cohort, a decrease in
deuterium-labeled TGs was observed in both the eWAT and sWAT of test cohorts. The
deuterium-labeled TG(16:0/16:1/16:1)[iso3] in eWAT significantly declined at 2 weeks
and

a

further

decrease

was

found

at

4

weeks.

While

deuterium-labeled

TG(16:0/16:0/18:1)[iso3] in sWAT significantly declined at 2 weeks, no further decrease
was found at 4 weeks. Time course changes for other deuterium-labeled TGs in liver and
WAT were listed in Table 4 and Table 5, respectively.
Figure

11

shows

that

the

time

course

trajectory

of

triacylglycerol

TG(16:0/18:2/20:4)[iso6] without 2H label in liver samples of control cohort and test
cohort. This TG molecule represents hepatic TGs which are synthesized from the dietary
fats or from de novo lipogenesis, because it did not incorporate any deuterium. In the
liver of control cohort, this TG molecule did not change at 2 weeks but increased at 4
weeks. Surprisingly, the test cohort showed a remarkable increase at 2 weeks compared
to time 0, and a further increase at 4 weeks. The abundance of this TG molecule in the
test cohort was significantly higher than that in the control cohort at both 2 and 4 weeks.

52

Figure 10. Sample time course trajectories of deuterium labeled triacylglycerols detected in
liver, eWAT and sWAT samples.(A) TG(16:0/18:2/20:4)[iso6] with one 2H label and one
Na+ as adduct ion in liver samples. (B) TG(16:0/16:1/16:1)[iso3] with one 2H label and an
adduct ion of Na+ eWAT samples. (C) TG(16:0/16:0/18:1)[iso3] with one 2H label and an
adduct ion of Na+ in sWAT samples
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Figure 11. Time course trajectory of triacylglycerol TG(16:0/18:2/20:4)[iso6] without any
deuterium labeling in liver samples.
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3.3.4.

Alterations of Hepatic Neutral Lipid and WAT Mass

To determine an overall change in lipid homeostasis at the liver-WAT axis, neutral lipid
in the liver and WAT mass were measured. As shown in Figure 12, oil red O staining of
neutral lipid on cryostat liver sections clearly demonstrated accumulation of lipid droplets
in the hepatocytes of alcohol-fed mice at 2 weeks. Further increases in number and size
of the lipid droplets were observed at 4 weeks. In contrast to neutral lipid accumulation in
the liver, WAT mass was significantly lower in the alcohol-fed mice compared to the
controls (Figure 13). The weights of both eWAT and sWAT from control mice were
increased at 2 weeks and a further increase was found at 4 weeks. However, the weights
of both eWAT and sWAT from alcohol-fed mice did not change at either 2 weeks or 4
weeks, leading to an increased difference between the control and alcohol mice along the
4 weeks of experiment. The time course changes in WAT to body weight ratio showed
similar trends to that of WAT mass.
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Figure 12. Time course changes of hepatic lipid content. Hepatic neutral lipid detected by Oil
red O staining of cryostat liver sections. Alcohol exposure increased hepatic neutral lipid
(lipid droplets) gradually along the 4 weeks of experiment.
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Figure 13. Time course changes of WAT tissues.(A) WAT mass. The weights of both
eWAT and sWAT in control mice increased gradually during the 4 weeks of experiment.
However, the alcohol-fed mice did not show weight change in both eWAT and sWAT at
either 2 weeks or 4 weeks. (B) WAT to body weight ratio (%). Data are expressed as mean ±
SD (n=6-8). Statistical differences were analyzed by ANOVA followed by Bonferroni post
hoc comparison, and means without a common letter differ at p<0.05.
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Table 5. List of triacylglycerols in sWAT and eWAT identified with significant concentration
changes between the control cohort and the test cohort at two and four weeks.
WAT

Metabolite common name

Adduct
ion

No. 2H

Time
(Week)

m/z

p-value

Fold change
(T/C)a

2

879.7446

2.1×10-2

0.74

TG(16:1/18:2/20:4)[iso6]

H+

2

2

880.7507

3.9×10-2

0.69

TG(16:0/18:1/18:2)[iso6]

Na+

1

4

826.7013

1.7×10-3

0.28

TG(16:0/16:1/16:1)[iso3]

Na+

1

4

879.7446

1.5×10-2

0.74

TG(16:1/18:2/20:4)[iso6]

H+

2

2

826.7017

4.1×10-4

0.38

TG(16:0/16:1/16:1)[iso3]

Na+

1

2

850.7013

1.3×10-2

0.68

TG(16:1/16:1/18:2)[iso3]

Na+

1

2

854.7334

-3

2.7×10

0.58

TG(16:0/16:1/20:4)[iso6]

+

H

1

2

855.7378

1.9×10-2

0.70

TG(16:0/16:0/18:2)[iso3]

Na+

2

4

828.7174

1.6×10-2

0.19

TG(16:0/16:1/16:1)[iso3]

Na+

3

4

854.7334

1.5×10-2

0.54

TG(16:0/16:1/20:4)[iso6]

H+

1

4

855.7378

4.4×10-2

0.48

TG(16:0/16:0/18:2)[iso3]

Na+

2

4

856.7482

-3

2.2×10

0.49

TG(16:0/16:0/18:1)[iso3]

Na

+

1

4

879.7445

1.5×10-2

0.73

TG(16:1/18:2/20:4)[iso6]

H+

2

4

880.7498

7.7×10-3

0.77

TG(16:0/18:1/18:2)[iso6]

Na+

1

sWAT

eWAT

a. Fold-change is the ratio of average peak area of a metabolite in the test cohort (T) to
that in the control cohort (C).

3.3.5.

Routine Parameters

Table 6 listed the results of routine parameters including body weight, liver weight, liver
to body weight ratio, and plasma ALT activity and FFA concentration. The test cohort
showed a lower body weight but a higher liver weight, leading to a significant increase in
liver/body weight ratio at both 2- and 4-week time points. The plasma ALT activity level,
an indicator of liver injury, was elevated in the test cohort at both time points. The plasma
triacylglycerol level was also increased in the test cohort at 4-week. However, plasma
cholesterol and FFAs was not affected by alcohol exposure.
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Table 6. Body weight, liver weight and plasma parameters of the control cohort and the test
cohort at two and four weeks.

2 weeks

4 weeks

Control

Test

Control

Test

Body weight (BW, g)

28.6±0.9 a

26.9±1.3 a

32.4±2.7 b

27.9±1.2 a

Liver weight (g)

1.06±0.04 a

1.16±0.05 b

1.10±0.04 ab

1.32±0.08 c

Liver/BW ratio (%)

3.69±0.22 a

4.33±0.30 b

3.41±0.16 a

4.77±0.21 c

ALT (U/L)

20.4±9.1 a

48.2±9.1 b

25.6±3.1 a

58.6±12.6 b

Triacylglycerol (mg/dL)

93.2±10.4 a

130.5±24.7 ab

110.4±11.3 a

171.9±47.7 b

Cholesterol (mg/dL)

121.7±19.6

107.1±14.8

110.7±10.3

101.4±10.3

FFA (mg/dL)

0.36±0.02

0.31±0.05

0.34±0.05

0.33±0.07

Data are expressed as mean ± SD (n=6-8). Statistical differences were analyzed by
ANOVA followed by Bonferroni post hoc comparison, and means without a common
letter differ at p<0.05.

3.4. Discussion
TGs are the group of most abundant lipids in liver, eWAT and sWAT. Analysis of the
abundance changes of TGs is enough for us to test our hypothesis. Therefore, the
methanol/water phase of metabolite extract from mouse tissues was discarded during the
process of metabolite extraction, while the organic phase was used for analysis. It is
possible that the regulations of other types of metabolites are also changed besides TGs
during the mouse feeding period. However, the changes of these metabolites are not in
the scope of this study.
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3.4.1.

Biological Experiment Design

A two-stage animal feeding experiment was performed in this study to differentiate the
hepatic lipids synthesized from the fatty acids transported back from adipose tissue from
that synthesized using fatty acids from de novo lipogenesis. It is expected that majority of
the lipids synthesized in the stage-one experiment were incorporated with a certain
number of deuterium atoms, and most of them were transported and stored in WAT. The
purpose of the stage-two experiment was to induce fatty liver in the test cohort and to use
the mice in the control cohort as reference to monitor the lipid concentration change in
the mice of the test cohort.
During the stage-two experiment, lipids were continuously synthesized in the mouse
livers in both the test and the control cohorts. The lipids synthesized from the uptake of
dietary fats should not incorporate any deuterium atoms, except a very small fraction of
naturally occurring deuterium in the dietary fats. Therefore, two forms of lipids should be
present in mouse liver: deuterium incorporated lipids and non-deuterium incorporated
lipids. In case of the control cohort, the deuterium incorporated lipids were synthesized
during the stage-one experiment while the non-deuterium incorporated lipids were
synthesized in the stage-two experiment.

3.4.2.

Statistical Significance Tests

Compared to the levels of deuterium incorporated TGs in the control cohort, the
significant increase of the deuterium incorporated TGs in the test cohort of liver samples
(Table 4) indicates that extra deuterium incorporated fatty acids were used for the
synthesis of TGs in alcoholic fatty liver at 2 and 4 weeks. The only source of the extra
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deuterium incorporated fatty acids is the WATs, where the deuterium incorporated fatty
acids were stored in the form of TGs during the stage-one experiment. Therefore, a
reasonable explanation to the increase of deuterium incorporated TGs in alcoholic fatty
liver in the test cohort is that the deuterium incorporated fatty acids were transported back
from the WAT after lipolysis due to alcohol consumption. Indeed, such an explanation is
further substantiated by the decrease of deuterated TGs in eWAT and sWAT,
respectively (Table 5). This supports our hypothesis, i.e., alcohol consumption
stimulates lipolysis in the WAT of mice, leading to release of fatty acids, which are
transported back and deposited in the liver for the synthesis of TGs.

3.4.3.

Temporal Analysis

Figures 10A demonstrates that portions of the accumulated TGs in fatty liver were
synthesized using deuterium incorporated fatty acids that were transported back from the
WAT due to lipolysis, while Figure 10B and 10C demonstrate a significant abundance
decrease of the deuterated TGs in eWAT and sWAT, respectively. These results reveal a
direct link between WAT fatty acid release and hepatic TG deposition in the development
of alcoholic fatty liver. A previous study also demonstrated that diminishing lipid storage
function in WAT by over-expressing leptin-receptor b (lpr-b) on the aP2-lpr-b promoter
(aP2lepr-b transgene) in db/db mice attenuated obesity after high fat feeding[113].
However, the aP2lepr-b transgene significantly increased liver weight and triglyceride
concentrations, and accelerated the development of diabetes. Therefore, WAT
dysfunction in lipid storage could be an important determinant in the pathogenesis
alcoholic or nonalcoholic fatty liver.
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Figure 11 displays the time course trajectory of triacylglycerol TG(16:0/18:2/20:4)[iso6]
without any deuterium labeling in liver samples. This TG molecule is synthesized by
using fatty acids from dietary source and/or hepatic de novo lipogenesis rather than by
using fatty acids transported back from the WAT. The time dependent abundance of this
metabolite in the test sample is always higher than its abundance in the control sample at
both 2 weeks and 4 weeks. These data indicate that fatty acids from the WAT are not the
sole source of TG synthesis, and fatty acids from diet and/or de novo synthesis also
contribute to the development of alcoholic fatty liver.

3.4.4.

WAT Dysfunction and Fatty Liver

Time course changes in WAT weight (Figure 13) demonstrated that WAT mass in
control mice significantly increased along the 4 weeks of feeding. Surprisingly, the WAT
mass of alcohol fed mice did not changed at either 2 weeks or 4 weeks compared to time
0, indicating a loss of the lipid storage function. A previous study has reported that
alcohol feeding to rats reduced total body fat content due to an increase of TG turnover in
rats, as indicated by a 2.3-fold increase in TG degradation with no significant change in
TG synthesis[102]. Our previous report also showed that alcohol exposure activates
lipolysis pathways in WAT, thereby accelerating fatty acid release[105]. Adipose
lipolysis is regulated positively by catecholamine and negatively by insulin[114].
Previous studies suggested that alcohol-increased lipolysis is most likely through
disturbing

insulin

signaling

rather

than

enhancing

catecholamine-mediated

lipolysis[102,105,115]. Insulin negatively regulates lipolysis, and phosphodiesterase 4
(PDE4) and activating protein phosphatase 1 (PP1) mediate insulin signaling via reducing
cellular cAMP level and dephosphorylating hormone sensitive lipase (HSL),
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respectively[114].

Although the adipose PDE4 was not affected in the WAT of

alcohol-fed rats[102], our previous study showed that PP1 protein level was reduced in
the WAT of alcohol-fed mice[105]. We also found that chronic alcohol exposure
up-regulated negative regulators of insulin signaling, including phosphatase and tensin
homolog (PTEN) and suppressor of cytokine signaling 3 (SOC3). In addition to lipid
storage dysfunction, alcohol exposure also inhibited expression and secretion of
adipokines including adiponectin and leptin in WAT[116-118]. Both adiponectin and
leptin critically modulate hepatic lipid metabolism toward reduction of lipid content in
the liver. Normalizing plasma adiponectin or leptin level was associated with attenuation
of alcoholic fatty liver[119-121]. Therefore, adipose tissue dysfunction may contribute to
the development of alcoholic fatty liver by directly supplying fatty acids for hepatic TG
synthesis or indirectly disturbing adipokine regulation of hepatic lipid metabolism.

3.4.5.

Alcohol-induced Hepatic Lipid Dyshomeostasis

Alcohol exposure may disturb hepatic lipid metabolism in multiple pathways, including
fatty acid uptake, fatty acid oxidation, de novo lipogenesis and lipid export[116,122].
The present study demonstrated that alcohol exposure causes a reverse transport of TGs
from WAT to the liver. Liver plays a central role in lipid metabolism, but it does not store
lipid at physiological condition. Balance between TG synthesis and export is a key
determent of hepatic lipid homeostasis[123,124]. Fatty acids from either blood or de novo
synthesis are converted to TGs which are exported to the blood in the form of very low
density lipoproteins (VLDL) for use or storage by the peripheral organs. Even though
alcohol induces hepatic influx of fatty acids, fatty liver should not be developed as long
as the liver can efficiently secrete TGs into the blood. Therefore, impaired VLDL
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secretion should co-exist with hepatic fatty acid influx in the development of alcoholic
fatty liver. The present study shows that the liver of alcohol-fed mice accumulated TGs
synthesized by using fatty acids of both deuterium labeled from WAT source and
non-deuterium labeled from dietary fats or de novo lipogenesis. These data suggest that
alcohol blunted lipid export. The authors believe that the increased blood TG levels in the
test cohort at 4 weeks may indicate an impaired TG uptake from VLDL in WATs, rather
than an increased hepatic TG secretion. Indeed, our previous study demonstrated that
alcohol exposure significantly reduced the rate of VLDL-TG secretion from the liver to
the blood[104, 106]. Disruption of VLDL secretion is likely an important mechanism
underlying alcoholic fatty liver, because improvement of VLDL secretion was associated
with attenuation of alcoholic fatty liver by zinc, betaine or hepatocyte growth
factor[104,125,126]. Further investigations are required to determine the mechanisms of
how alcohol exposure suppresses lipid export function of the liver.

3.5. Conclusions
We used an analytical method of employing high-resolution mass spectrometry in
combination with metabolite deuterium labeling for the analysis of triacylglycerol. A
two-stage mouse feeding schema was designed, where all mice were first fed with
deuterated water to label WAT TGs (stage one), followed by pair-feeding an alcohol or
isocaloric maltose dextrin control liquid diet for two or four weeks. Hepatic lipids
extracted from the livers, eWAT and sWAT tissues were detected by FTICR–MS and
LTQ-MS/MS. All observations in this study, including the increase of TGs in the test
cohort of liver, the simultaneous decrease of TGs in the test cohort of eWAT and sWAT,
and the agreement between the metabolomics data and the histological data demonstrate
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that chronic alcohol exposure disturbs lipid homeostasis at the adipose tissue-liver axis
and therefore, support our hypothesis, that is, alcohol consumption stimulates lipolysis of
the WAT and leads to an excess release of fatty acids which are transported to the liver
and deposited as TGs. Furthermore, accumulation of TGs synthesized from fatty acids
from dietary source or de novo lipogenesis also contributes to the pathogenesis of fatty
liver.
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CHAPTER 4
THE EFFECTS OF CHRONIC ARSENIC
EXPOSURE IN A MOUSE MODEL OF
DIET-INDUCED FATTY LIVER DISEASE
4.1. Introduction
Diet-environment interactions play an important role in the development and progression
of many human diseases, including fatty liver disease (FLD). According to the prevailing
two hit hypothesis[127], dietary factors such as excessive fat consumption contribute to the
formation of fatty liver, which makes the liver susceptible to a second hit which promotes
the progression to more severe liver injury. Several factors have been shown to mediate the
progression from simple steatosis (fatty liver) to steatohepatitis (fatty liver with
inflammation and cell death)[128] and environmental agents that activate these factors can
contribute to the extent of liver injury[129,130]. For example, arsenic was recently shown
to contribute to the progression of diet-induced fatty liver disease by increasing
inflammatory mediators in mouse liver[131].
Although several regions in the United States where municipal water supplies and private
artesian wells have arsenic concentrations exceeding the Maximum Contaminant Level of
10 parts per billion (ppb) set by the World Health Organization and the Environmental
Protection Agency, arsenic concentrations can reach much higher concentrations in
places like Bangladesh and West Bengal[132]. Epidemiological studies in these
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highly-exposed populations have revealed strong links between arsenic exposure and skin
lesions, hypertension, cardiovascular disease, respiratory disease, and cancer[133].

In

the liver, high arsenic exposure results in hepatomegaly, portal hypertension,
non-cirrhotic portal fibrosis and cancer[134]. It is unclear whether the liver is a primary
target of toxicity in people exposed to lower levels of arsenic, such as those seen in the
United States. It is more likely that the adverse effects of arsenic on the liver will depend
on the presence of other sensitizing factors like fatty liver disease.
It has been reported that mice fed a diet high in fat and cholesterol (the so-called Western
Diet) for 10 weeks developed steatosis, while simultaneous exposure to drinking water
contaminated with arsenic resulted in much more inflammation and cell death[131]. In
that study, 5 parts per million (ppm) arsenic had no effect on the livers of mice fed a low
fat control diet. While this concentration is higher than those to which produce
hepatotoxicity in human populations[134] the absorption, distribution and metabolism of
arsenic is much different in mice than in humans. Indeed, a recent report showed that it
took 10 times higher concentrations of drinking water (arsenic 50 ppm) to achieve liver
arsenic concentrations similar to those seen in humans exposed to arsenic in West Bengal
[135].
To better understand the interactions between arsenic and diet-induced fatty liver disease,
we employed high throughput comprehensive two-dimensional gas chromatography
time-of-flight mass spectrometry (GC×GC–TOF MS) to analyze liver metabolites altered
by arsenic, a high fat diet, and the combination of the two. GC×GC–TOF MS is one of
the most powerful analytical platforms for metabolomics analyses. It is an emerging
technology that provides considerably more chemical selectivity than GC-MS. It uses two
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capillary GC columns connected via a thermal modulator to achieve a high degree of
separation of metabolites[136-138]. Compared to the 15–60 m length of the first
dimension column, the length of the second dimension column is very short, in general
only 0.5–2 m. These two GC columns usually have different stationary phases to
maximize the orthogonality of the two-dimensional separation system to achieve high
peak capacity. The analytes co-eluted from the first column are further separated in the
second column because of the difference of column temperature and the chromatographic
polarities. The further separated analytes are directed to a high capacity time-of-flight
mass spectrometry system for detection. The GC×GC–TOF MS platform offers
significant advantages over other metabolomics platforms for analysis of complex
samples, including an order-of-magnitude increase in separation capacity, significant
increase in signal-to-noise ratio and dynamic range, and improvement of mass spectral
deconvolution and similarity matches[139,140]. Presently, GC×GC-MS has not been
widely used for large-scale broad-spectrum biomarker discovery most likely due to the
increased difficulty of data analysis. New bioinformatics tools have recently emerged that
greatly decrease the personnel time necessary to properly process the GC×GC-MS
data[141-143] making this approach feasible for large-scale metabolomics studies[3, 5].
Our in-house developed bioinformatics tools MetPP combined with GC×GC-MS
bioanalytical platform, were used here.
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4.2. Experimental
4.2.1.

Materials and Reagents

Chemicals used in this experiment include organic solvents (methanol, chloroform and
pyridine), amino acids (glycine,
L-methionine, L-aspartic

L-serine, L-proline, L-phenylalanine, L-threonine,

acid, L-glutamic acid,

L-lysine, L-histidine,

and

L-alanine),

organic acids (adipic acid, fumaric acid, malonic acid, oxalic acid, succinic acid), fatty
acids (butyric acid, dodecanoic acid, hexadecanoic acid, heptadecanoic acid, heptanoic
acid, nonanoic acid, octadecanoic acid, pentadecanoic acid, tetradecanoic acid,
tridecanoic acid), oximation and derivatization reagents (tert-butyldimethylchlorosilane
(TBDMSCI) and N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA)).
All of these chemicals were purchased from Sigma-Aldrich Corp. (St. Louis, MO, US). A
deuterated semi-volatile internal standard (ISTD) mixture containing acenaphthene-d10,
chrysene-d12, 1,4-dichlorobenzene-d4, naphthalene-d8, perylene-d12, phenanthrene-d10
was purchased from Restek Corp. (Bellefonte, PA, US)

4.2.2.

Spiked-in Samples

To extract metabolites from mouse liver, a 200 μL aliquot of homogenized liver sample
was mixed with 800 μL of methanol and vortexed for 1 min, followed by centrifugation
at 4 °C for 10 min at 15,000 rpm. 0.8 mL of the top solution was aspirated into a plastic
tube and dried by N2 flow. After dissolving the dried sample with 100 μL of pyridine,
100 μL of MTBSTFA was added and the derivatization was lasted for 1 hour at 70 °C.
A mixture of 28 acid standards was prepared at a concentration of 100 μg/mL per acid.
The acids included glycine, L-alanine, L-proline, L-cystine, L-histidine, L-phenylalanine,
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L-tyrosine, L-lysine, L-glutamic

acid, L-methioneine,

L-proline, L-serine, L-threonine,

L-tryptophan, L-valine, L-leucine,

adipic acid, butyric acid, fumaric acid, malonic acid,

oxalic acid, succinic acid, dodecanoic acid, docosanoic acid, hexadecanoic acid,
heptadecanoic acid, octadecanoic acid, tetradecanoic acid, nonadecanoic acid, tridecanoic
acid, hepadecanoic acid, heptanoic acid, nonanoic acid and pentadecanoic acid. 100 μL
of the acid mixture was added to 100 μL MTBSTFA at 70 °C and kept 1 hour for
derivatization.
Ten μL of the acid mixture was added to the first vial, while 20, 40, 50 and 80 μL of the
acid mixture were added to the other vials, respectively. Twenty μL of derivatized liver
extract sample and 5 μL of ISTD at a concentration of 200 μg/mL were added to each of
the five vials, respectively. Pyridine was then added to each of the 5 vials to make the
total volume of each aliquot to 105 μL. This resulted in five samples with spiked-in acid
standards. The acid concentration of the amount of spiked-in acid in the 5 samples is
approximately 6.4 μg/mL, 12.8 μg/mL, 25.6 μg/mL, 32.0 μg/mL and 51.2 μg/mL,
respectively. The ratio of the concentrations is 1:2:4:5:8 in terms of the amount of
spiked-in standards. A blank sample was also prepared in parallel without adding acid
standards and liver extract. Each of the five samples was injected 6 times on the
GC×GC-TOF MS instrument to generate one sample group, respectively.
Of these 28 acids, 23 of them already exist in mouse liver including adipic acid, fumaric
acid, malonic acid, oxalic acid, dodecanoic acid, hexadecanoic acid, heptadecanoic acid,
decanoic acid, nonanoic acid, octadecanoic acid, pentadecanoic acid, tetradecanoic acid,
glycine, L-alanine, L-glutamic acid, L-leucine, L-lysine, L-methionenine, L-phenylanine,
L-proline, L-serine, L-threonine,

and L-valine. The concentration ratio of these metabolites
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among the five sample groups is not 1:2:4:5:8, due to the presence of these metabolites in
the mouse liver extract.

4.2.3.

Animals and Diets

Four week old male C57Bl/6J mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). Mice were housed in a pathogen-free barrier facility accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care. Food and tap
water were allowed ad libitum. The procedures of animal care were approved by the
University of Louisville Institutional Animal Care and Use Committee.
All mice were fed AIN-76A Purified diet (Harlan Laboratories, Madison, WI) for one
week to minimize the potential confounding factor of arsenic present in standard
laboratory chow [144].

Mice were exposed to sodium arsenite (5 ppm in tap water) or

tap water for one week prior to initiating feeding with either low fat diet (13% of calories
from fat) or high fat diet (42% of calories from fat) (diets TD.08485 and TD.88137,
Harlan Laboratories, Madison, WI) for 10 weeks. This exposure level of arsenic was
shown in literature[131] to cause no overt liver damage in mice fed low-fat diet, but to
exacerbate high fat diet-induced liver injury. Four different treatment groups were
evaluated in this study: 6 mice fed a low fat diet and tap water (sample group LFD); 6
mice fed a low fat diet and tap water containing sodium arsenite (sample group LFD+As);
5 mice fed a high fat diet and tap water (sample group HFD); 6 mice fed a high fat diet
and tap water containing sodium arsenite (sample group HFD+As). Food and water
consumption were measured twice a week. Body weight was measured once a week. For
termination, mice were anesthetized with ketamine/xylazine (100/15 mg/kg i.m.).
Portions of liver tissue were frozen immediately in liquid nitrogen.
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4.2.4.

Metabolite Sample Preparation from Mouse Liver

The liver tissue of each mouse was weighed and then homogenized for 2 min after adding
water at a ratio of 100 mg liver tissue/mL water. The homogenized sample was then
stored at –80 °C until use. A 100 µL aliquot of the homogenized liver sample and 400 µL
methanol were mixed and vortexed for 1 min followed by centrifugation at room
temperature for 10 min at 15000 rpm. 400 µL of the supernatant was aspirated into a
plastic tube and dried by N2 flow. The metabolites extracts were then dissolved in 40 µL
ethoxyamine hydrochloride solution (30 mg/mL) and vigorously vortex-mixed for 1 min.
Methoxymation was carried out at 70 °C for 1 hour. After adding 40 µL MTBSTFA
mixed with 1% TBDMSCI, derivatization was carried out at 70 °C for 1 hour. Stock
solutions were then transferred to GC vials for analysis. The methoxymation and
derivatization were prepared just before GC×GC–TOF MS analysis.

4.2.5.

GCGC–TOF MS Analysis

The LECO Pegasus 4D GC×GC –TOF MS instrument was equipped with an Agilent
6890 gas chromatograph and a Gerstel MPS2 auto-sampler (GERSTEL Inc., Linthicum,
MD), featuring a LECO two-stage cryogenic modulator and secondary oven. The primary
column was a 60 m × 0.25 mm 1dc × 0.25 μm 1df, DB-5ms GC capillary column (phenyl
arylene polymer virtually equivalent to a (5%-phenyl)-methylpolysiloxane). A second
GC

column

of

1

m

×

0.25

mm

1

dc

×

0.25

μm

2

df,

DB17ms

((50%-phenyl)-methylpolysiloxane) was placed inside the secondary GC oven after the
thermal modulator. Both columns were obtained from Agilent Technologies (Agilent
Technologies J&W, Santa Clara, CA). The helium carrier gas (99.999% purity) flow rate
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was set to 1.0 mL/min at a corrected constant flow via pressure ramps. The inlet
temperature was set at 280 °C. The primary column temperature was programmed with
an initial temperature of 60 °C for 0.5 min and then ramped at 5 °C /min to 280 °C and
maintained for 12 min. The secondary column temperature program was set to an initial
temperature of 70 °C for 0.5 min and then also ramped at the same temperature gradient
employed in the first column to 280 °C, accordingly. The thermal modulator was set to
+20 °C relative to the primary oven, and a modulation time of PM = 2.5 s was used. The
mass range was set as 45−1000 m/z with an acquisition rate of 200 mass spectra per
second. The ion source chamber was set at 230 °C with the transfer line temperature of
280 °C, and the detector voltage was 1680 V with electron energy of 70 eV. The
acceleration voltage was turned on after a solvent delay of 775 s. The split ratio was set at
40:1.

4.2.6.

Data Analysis

The GC×GC–TOF MS data were processed using LECO’s instrument control software
ChromaTOF for peak picking and tentative metabolite identification, followed by
retention index matching, peak merging, peak list alignment, normalization, and
statistical significance test. For metabolite identification using ChromaTOF, each
chromatographic peak was tentatively assigned to a metabolite if its experimental mass
spectrum and a database spectrum have a spectral similarity score no less than 600. Note
that the maximum spectral similarity score is 1000. Peak merging and peak list alignment
were carried out using DISCO software[17], while the retention index matching was
performed using iMatch software with the p-value threshold set as p ≤ 0.001[18]. The
pairwise two-tail t-test was used to determine whether a metabolite has a significant
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abundance difference between sample groups by setting the threshold of false discovery
rate q ≤ 0.2.
To further verify the identification of metabolites detected with significant abundance
difference between sample groups, commercially available authentic standards of these
metabolites were analyzed on GC×GC–TOF MS under the same experimental conditions
as the biological samples analyzed. A tentative metabolite assignment was considered as
a correct identification only if the experimental information of the authentic metabolite
agreed with the corresponding information of the chromatographic peak in the biological
samples, i.e., difference of the first dimension retention time ≤ 10 s, difference of the
second dimension retention time ≤ 0.06 s, and the mass spectral similarity ≥ 700.

4.2.7.

Metabolite Relative Quantification

To measure the accuracy of recognizing the spiked-in metabolites from the experimental
data, the receiver operating characteristic (ROC) curve is applied, which is created by
plotting the true positive rate (TPR) vs. the false positive rate (FPR) at various threshold
settings. TPR, PPV and their harmonic mean F1 score are calculated as follows:

TPR 

PPV 

F1 

TP
TP  FN

TP
TP  FP

(4.1)

(4.2)

2  TPR  PPV
TPR  PPV
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(4.3)

where TP (true-positive) is the number of spiked-in metabolites that were detected as
molecules with significant peak area changes between two testing sample groups by
statistical analysis, FP (false-positive) is the number of molecules that were not the
spiked-in metabolites but detected as molecules with significant peak area changes, and
FN (false-negative) is the number of spiked-in metabolites that were not detected as
molecules with significant peak area changes. TPR is called recall and PPV precision and
their harmonic mean F1 score can be used as an accuracy of the statistical significant test.
Furthermore, the area under curve (AUC) in the ROC curve is equal to the probability of
positive outcomes being higher than the negative ones. The higher the AUC score is, the
better the observed accuracy of the test for statistical significance.

4.3. Results
Figure 14 depicts the analysis workflow of this study. Metabolites were first extracted
from mouse liver using solvent of methanol and water. The extracted metabolites were
then analyzed on GC×GC–TOF MS instrument after derivatization. A suite of
bioinformatics tools were then employed for metabolite identification, quantification and
pathway analysis.
GC×GC–TOF MS instrument data provide four pieces of information for each metabolite,
the first dimension retention time 1tR, the second dimension retention time 2tR, fragment
ion m/z, and peak height of each fragment ion. The information of fragment ion m/z and
peak height forms the mass spectrum of the metabolite. Figure 15 is a contour plot of the
GC×GC–TOF MS data acquired from a sample randomly selected from the sample group
LFD. The color of each data point is the signal intensity.
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Bioanalytical Analysis

Liver tissue

Metabolites Extraction
and Derivatization
GC ×GC-TOF MS

Bioinformatic Analysis

Chroma TOF and MetPP
Significant Metabolites
Authentic Standards
Confirmation

Figure 14. Workflow of metabolomics Study by GC×GC-TOF MS.
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Figure 15. Sample GC×GC–TOF MS chromatograms of metabolite extract from mouse
liver. The x-axis is the first dimension retention time 1tR in seconds. The y-axis is the second
dimension retention time 2tR in seconds. The color bar shows the signal intensity of each peak
plotted on the chromatogram in total ion current.

The instrument data were first processed using commercial software ChromaTOF for
peak picking and initial compound identification using the vendor recommended
parameters, and the information of the top 1500 abundant chromatographic peaks were
reported. By setting the threshold of spectral similarity ≥ 600, about 570-730
chromatographic peaks were assigned to compounds in each sample, while the remaining
chromatographic peaks were assigned as unknowns. The average peak area of the
chromatographic peaks with initial identification results is about 6 times larger than the
average peak area of the chromatographic peaks assigned as unknowns. The
chromatographic peaks with positive identifications were further subjected for retention
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index matching using iMatch algorithm. By setting the threshold p ≤ 0.001, about
380-520 compounds had correct retention index values in each sample and the remaining
chromatographic peaks were re-assigned as unknowns. All retention index matched
compounds were used for alignment using DISCO algorithm. A total of 402 peaks were
aligned. The aligned metabolites were further filtered by removing compounds detected
in the blank samples as well as the compounds that detected in less than 75% of samples
in each sample group. By doing so, about 100 metabolites left between two sample
groups for statistical significance test and FDR analysis.
The ability of the platform to accurately identify metabolites with significant abundance
differences between two sample groups was assessed by spiking different concentrations
of a mixture of standards into a sample. Figure 17 shows the receiver operator curves
produced by these spike-in experiments. A large value of area under curve (AUC) in the
receiver operating characteristic (ROC) curve demonstrates that the analytical platform
and the data analysis methods used in this study are effective in recognizing the
metabolites with significant differences.

4.3.1.

Metabolite Identification

Metabolite identification was done in three sequential steps in this study: mass spectral
matching, retention index matching, and comparison with authentic standards. It is
common that multiple distinct chromatographic peaks can be assigned to the same
metabolite by mass spectral matching, due to limited accuracy of the identification
algorithm[139,140].

For

example,

glycine,

N-(tert-butyldimethylsilyl)-,

tert-butylsimethylsilyl ester was assigned to three distinct chromatographic peaks with
two-dimensional retention times of (1655 s, 1.155 s), (1845 s, 1.055 s) and (1850 s, 1.045
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s), respectively. The spectral similarity of these three assignments to the mass spectra in
the NIST11 database was 872, 731 and 787, respectively. In order to reduce the rate of
false identification, we employed a second round of retention index matching to remove
the false positive identifications. By setting the threshold p ≤ 0.001 in iMatch software,
the chromatographic peaks with the two-dimensional retention time values of (1845 s,
1.055 s) and (1850 s, 1.045 s) were recognized as false identifications and excluded from
the downstream analysis, due to large retention index difference.
Metabolite identifications based on retention index matching were further confirmed by
comparison to authentic standards. For example, glycine was detected as a metabolite
with significant abundance changes between different sample groups. The retention time
values for the metabolite identified as glycine in the biological samples were (1655 s,
1.155 s). The authentic standard of glycine that was derivatized and analyzed on
GC×GC–TOF MS under the same conditions as the biological samples eluted at 1tR =
1655 s and 2tR = 1.165 s, which is very similar to the peaks eluted in the biological
sample with identical 1tR and a difference of 0.01 s in 2tR. The mass spectral similarity
between the authentic standards and the biological sample was 970, demonstrating the
correct identification of glycine from the biological samples.
Some metabolites tentatively assigned by mass spectrum matching and retention index
filtering were not compared to authentic standards because they were not available in our
laboratory. Because this technical verification was not performed, their identification
remained tentative. Tentatively-identified metabolites were considered as false
identifications and removed from the identification list, if they were recognized as drugs
or from non-mammalian animals during metabolic network analysis by the Ingenuity
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Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA). The
remaining tentatively-identified metabolites were included in subsequent analyses, but
they have been labeled as tentative in Tables 7 through 9.

4.3.2.

Metabolite Quantification

About 500-800 metabolites were identified in each mouse liver sample via mass spectral
matching. By setting p ≤ 0.001, 18.6% of the identified metabolites were confirmed by
the first dimension retention index matching and 51.8% were preserved due to the lack of
retention index information in the NIST11 database. However, 29.5% of the mass
spectral matched metabolites were removed due to the large first dimension retention
index deviation from the database values. The mean absolute deviation between the
database value and experimental retention index of the removed metabolites is 318 i.u.
with a standard deviation of 267 i.u. The corresponding values of the preserved
metabolites are 21 ±16 i.u.
After the retention time filtering, about 300–500 peaks were left in each sample for
alignment. Among the aligned peaks, the maximum value of the RSD for the first
dimensional retention time and the second dimensional retention time was only 3.15%
and 3.30%, respectively.
To study the abundance change of a metabolite between two testing sample groups, the
pairwise two-tail t-test was employed by setting the threshold of false discovery rate as q
≤ 0.2. A term fold-change was defined as the ratio of the large abundance value (peak
area) of a metabolite in one group divided by the small abundance value of the same
metabolite in the other group. A positive sign and a negative sign indicate the abundance
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increase and decrease in the testing sample group compared to the reference sample
group, respectively.
Figure 16 depicts a sample abundance distribution of metabolite glycine in sample groups
HFD and HFD+As. Glycine was detected by the statistical significance test as one of the
metabolites that have significant abundance changes between these two sample groups.
Compared with its abundance in the HFD group, glycine is 1.7-fold lower in the
HFD+As group with a p-value of 5.0×10–3.

Figure 16.

Abundance distribution of metabolite glycine in the samples of HFD+As group

and HFD group.The abundance test (pairwise two-tail t-test) shows that the regulation of this
metabolite in the HFD+As group is decreased with a fold change of 1.7 and a p-value of
5.0×10-3 comparing with HFD group.

Mice fed a high fat diet develop steatotosis[131]. To establish the metabolomic changes
that accompany this liver injury, the metabolites with significant differences in
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abundance between the HFD group and the LFD group were determined (Table 7). Eight
metabolites were increased and one metabolite was decreased in the HFD group relative
to the LFD group. As would be expected when comparing mice fed a diet high in fat to
mice fed a low fat diet, two of the increased metabolites were fatty acids, whereas none
of the decreased metabolite was fatty acids.
Table 8 shows the effects of arsenic in mice fed the low fat diet (LFD+As vs. LFD).
There were no signs of liver injury in either of these groups, but there were significant
metabolic differences resulting from arsenic exposure. The abundance of one metabolite
was decreased while seven metabolites were increased in the LFD+As group compared to
the LFD group. Three fatty acids were detected with significant regulation changes by
arsenic. The levels of two fatty acids were increased while one was decreased.
Table 9 presents the results of arguably the most important comparison in this study: the
metabolic differences between the HFD and HFD+As groups. Whereas the HFD
produces mild liver injury in the form of steatosis, co-exposure to arsenic results in even
more severe liver injury, with elevated markers of inflammation and cell death[131]. The
combination of arsenic and a high fat diet (HFD+As) resulted in abundance changes in
nine metabolites relative to the effect of a high fat diet alone (HFD), with six metabolites
decreasing and three metabolites increasing. The metabolites that were lower in the
HFD+As group were short-chain fatty acids, medium-chain fatty acids, the two acidic
amino acids, aspartate and glutamate, and the anti-inflammatory amino acid glycine. The
metabolites that were higher in the HFD+As group were the amino acids cysteine and
lysine, and the citric acid cycle intermediate, citric acid
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Table 7.

Metabolites with significance abundance difference between sample groups HFD
and LFD.

Name

p-value

1

2

CAS

Fold
Changea

Tetradecanoic acid

1.4×10-2

2323.8

1.228

544-63-8

1.5

Pentadecanoic acid

1.4×10

-4

2432.6

1.243

1002-84-2

2.3

L-Cysteine

3.0×10-5

2440.0

1.262

7048-04-6

1.7

L-Threonine

2.4×10-2

1900.5

1.208

72-19-5

2.1

L-Lysine

5.2×10-4

2625.7

1.272

56-87-1

-2.5

Pentanoic acid,
3-methyl-2-oxo- b

3.6×10-2

2205.1

1.363

6628-79-1

1.2

L-Methionine

1.3×10-2

2177.5

1.280

63-68-3

1.4

L-Glutamic

2.4×10-2

2510.0

1.244

56-86-0

1.5

3.8×10-6

2117.5

1.351

107-35-7

4.5

Taurine
a

acid

tR(s)

tR (s)

The sample group LFD is the reference group. “+” sign refers to abundance increase in

sample group HFD, while “ –” sign refers to abundance decrease in HFD group.
b

Tentative identification without technical verification using authentic standards.
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Table 8.

Metabolites with significance abundance difference between sample groups
LFD+As and LFD.

Name

p-value

1

2

CAS

Fold
Changea

Heptanoic acid

4.7×10-3

1397.5

1.158

111-14-8

-1.4

Dodecanoic acid

3.5×10

-3

2089.3

1.204

143-07-7

1.7

Pentadecanoic acid

3.3×10-2

2432.6

1.243

1002-84-2

1.3

L-Proline

1.2×10-2

1935.1

1.235

147-85-3

1.2

L-Cysteine

3.0×10-2

2440.0

1.262

7048-04-6

1.3

L-Methionine

3.0×10-3

2177.5

1.280

63-68-3

1.4

4-Aminobutanoic acid b

8.4×10-3

1926.5

1.188

56-12-2

1.5

-3

2205.1

1.363

6628-79-1

1.8

Pentanoic acid 3-methyl-2-oxoa

b

2.3×10

tR (s)

tR (s)

The sample group LFD is the reference group. “+” sign refers to abundance increase in

sample group LFD+As, while “ –” sign refers to abundance decrease in LFD+As group.
b

Tentative identification without technical verification using authentic standards.
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Table 9.

Metabolites with significance abundance difference between sample groups
HFD+As and HFD.

Name

1

p-value

tR (s)

2

tR (s)

CAS

Fold
Change
a

Dodecanoic acid

4.8×10-2

2089.3

1.204

143-07-7

-1.3

Glycine

5.0×10-3

1655.0

1.159

56-40-6

-1.7

α-Aminoisobutyric acid b

3.4×10-2

1686.9

1.166

594-61-6

-1.6

L-Glutamic

4.2×10-3

2510.0

1.244

56-86-0

-1.4

2-Hydroxybutyric acid

4.9×10-2

1642.4

1.135

600-15-7

-1.4

L-Aspartic

4.6×10-2

2385.0

1.225

56-84-8

-1.2

L-Cysteine

1.5×10

-2

2440.0

1.262

7048-04-6

1.4

Citric acid b

3.3×10-2

2911.1

1.593

77-92-9

1.7

L-Lysine

6.0×10-2

2625.7

1.272

56-87-1

1.7

a

acid

acid

The sample group HFD is the reference group. “+” sign refers to abundance increase in

sample group HFD+As, while “ –” sign refers to abundance decrease in HFD+As group.
b

Tentative identification without technical verification using authentic standards.

4.3.3.

Analysis of Spike-in Samples

A total of 30 samples were analyzed on GC×GC-TOF MS. Manual review of the peak
lists generated by ChromaTOF shows that the 28 spiked-in metabolites were correctly
identified in every sample. Of the 28 spiked-in metabolites, 23 metabolites were
originally present in mouse liver extract. Therefore, the concentrations of these 23
metabolites are different from the other 5 spiked-in metabolites in each sample group.
About 300 peak entries in each sample were assigned to a metabolite name via mass
spectral matching. For retention index matching, the confidence interval of the empirical
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distribution function of the absolute retention index deviation to its mean value was set as
p ≤ 0.001. 20.7% of the identified metabolites were confirmed by the first dimension
retention index matching and 53.5% were also preserved due to the lack of retention
index information in the NIST11 retention index database. However, 25.8% of the mass
spectral matched metabolites were removed due to the large first dimension retention
index deviation from the database values. The mean absolute deviation between the
database value and experimental retention index of the removed metabolites is 308 index
units (i.u.) with a standard deviation of 257 i.u. The corresponding values of the
preserved metabolites are 28 ± 12 i.u. All 28 spiked-in metabolites are preserved in each
of the 30 samples after the retention index matching. Metabolites butyric acid and
L-tryptophan

were preserved due to the lack of retention index values in the NIST11

database while the others were preserved by correct retention index match.
About 200–400 peaks were left in each sample for alignment. Peak picking is likely the
primary cause for such variation. By manual validation, all 28 spiked-in metabolites were
present in all 30 samples with a relative standard deviation (RSD) of the first and second
dimensional retention times of 0.07% and 0.55%, respectively, demonstrating a very
good stability of the instrument during the two-dimensional GC separation and a high
accuracy of ChromaTOF in determining peak location in the two-dimensional gas
chromatograms.
Figure 17 depicts the peak area distribution of the 28 spiked-in metabolites in G10 before
and after peak area conversion. A large variation in each box represents the peak area
variation of the same compound between the 6 samples. By design, each compound
should have the identical peak area among the 6 samples. However, ChromaTOF reports
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A

B

Figure 17.

Boxplot of peak area of the 28 spiked-in metabolites in G10 before reference

spectrum-based peak area conversion (A) and after the reference spectrum-based peak area
conversion (B). + refers to the values of peak area considered as outliers.
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only the peak area of a quant mass (a fragment ion that has the highest quality for
quantification), and it often chooses different quant mass for the same metabolite,
depending on the data. Of the 28 metabolites, 10 metabolites in at least one of the 6
samples have quant mass different from the other samples. For instance, compound 4
(oxalic acid) in Figure 17(A) has 2 quant mass values and the value of peak area has a
large deviation, ranging from 1,041,108 to 3,206,235. After reference spectrum-based
peak area conversion, the span of peak area is greatly reduced to 1,329,043–1,935,698
(Figure 17(B)), demonstrating the effectiveness of the reference spectrum-based peak
area conversion. The converted peak area values not only reduced the variation in peak
area, but also guarantee the consistency of the values of peak area across samples for the
downstream statistical analysis.
To demonstrate whether the concentration differences of the spiked-in metabolite
standards can be recognized from the alignment table, a two-tailed t-test was used to
check the mean difference of the peak area of each compound between sample groups
through different p-value settings. The true positive rate (TPR) and the false positive rate
(FPR) are used as measures for metabolite relative quantification. Figure 18 depicts the
ROC curve of recognizing the concentration difference of the spiked-in metabolite
standards between sample groups using the alignment results. As expected, the FPR
increases with the increase of TPR. The TPR levels off at 1.0 when the FPR reaches 0.9
between all the comparing sample groups. The AUC of the ROC curve of G10 vs. G20 is
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Figure 18.

The receiver operating characteristic (ROC) curve of the spike-in data. The area

under curve (AUC) of the three comparisons is 0.87, 0.71, and 0.81 for G20 vs. G10, G40 vs.
G10 and G40 vs. G20, respectively.

0.87, while the AUC of the ROC curve of G20 vs. G40 and G10 vs. G40 is 0.71 and 0.81,
respectively. A high value of AUC indicates a high accuracy of recognizing the
concentration difference of the spiked-in compounds between sample groups, which is
achieved on the basis of correct alignment of the spiked-in compounds. Moreover, it is
worth mentioning that the spiked-in metabolites that were not recognized as metabolites
with significant concentration difference between the two testing sample groups are all
present in the mouse liver extract before the addition of the mixture of authentic
standards. This means that the concentration differences of these metabolites between
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sample groups may be much smaller than 2:1 or 4:1, depending on the amount of the
metabolites in each sample of mouse liver extract.

4.4. Discussion
Multiple data analysis steps were involved in analysis of the GC×GC–TOF MS data in
this study. In order to control the false discovery rate, the experimental data were
analyzed using different values of FDR threshold including q ≤ 0.05, 0.1, 0.15, 0.2 and
0.3. The numbers of metabolites detected with significant abundance change between two
sample groups are listed in Table 10. It is generally known that the statistical power
increases as the FDR increases at a fixed sample size, while the power increases as the
sample size increases at a fixed FDR[145]. Consequently, a larger FDR threshold is
required to achieve a desirable power when the sample size is small. For this reason, we
selected q ≤ 0.2 to achieve a reasonable power due to the small sample size in this study.
Figure 19 depicts the clustering results of the four sample groups. The results presented
here demonstrate that both high dietary fat intake and environmental arsenic exposure
exert effects on liver metabolism, and that the combination of the two exposures yields a
unique metabolite profile that may offer some insight into the mechanisms of liver injury.
Previously, we showed that mice fed the so-called Western diet (a diet high in milk fat
and cholesterol) for 10 weeks gained more weight and had significantly more fat in their
livers than mice fed a low fat diet[131], consistent with other studies using this
diet[146,147]. Importantly, co-exposure to arsenic-containing drinking water resulted in
significantly greater inflammatory liver injury in this model[131], suggesting that arsenic
may be a second hit that promotes progression from steatosis to steatohepatitis[127].
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Figure 19.

Clustering analysis of the four sample groups using fuzzy C mean algorithm.

The input data were the abundance of all metabolites that were detected with significant
regulation changes between two or more sample groups when the FDR threshold q≤0.2.
(A) depicts the clustering results of all four sample groups. The overall clustering accuracy
reached 0.70. (B) displays the clustering accuracy between two sample groups.
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Table 10. The number of metabolites with significant differences between sample groups
with different values of FDR threshold. It should be noted that the number of metabolites
detected with significant difference between sample groups are different from these listed in
Tables 7, 8, 9. The number of metabolites listed in this table was directly calculated from the
alignment table. That is the identifications of these compounds were not yet confirmed using
the methods described in section 4.3.1.

Sample Groups

HFD+As HFD vs. LFD+As
vs. HFD
LFD
vs. LFD

HFD+As vs.
LFD+As

q ≤ 0.05

9

8

0

25

q ≤ 0.1

14

12

6

30

q ≤ 0.15

15

20

10

31

q ≤ 0.2

25

20

12

36

q ≤ 0.3

34

30

16

39
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In the context of the two hit hypothesis of steatohepatitis[127], one should consider how
the metabolic changes elicited by the first hit (high fat diet) are affected by the second hit
(arsenic). The high fat diet significantly altered nine metabolites (Table 7), and the
addition of arsenic resulted in further alterations in three of these metabolites (Table 9).
The HFD-induced increase in cysteine was amplified, whereas the increase in glutamate
was blocked, by co-exposure to arsenic. Also, the HFD-induced decrease in lysine was
reversed by arsenic. Furthermore, six additional metabolites were changed by the
combination of the high fat diet and arsenic that were not altered by the high fat diet
alone. Among these, glycine was decreased by the combination of arsenic and a high fat
diet. Therefore, all three of the amino acids that constitute the antioxidant glutathione
(glutamate, cysteine and glycine) were altered, with glutamate and glycine levels lower
and cysteine levels higher. Under normal conditions, cysteine concentrations are near the
Km for the rate-limiting enzyme glutathione synthesis[148], and an increase in cysteine
would be expected to increase the rate of synthesis. Indeed, Literature reported that mice
exposed to arsenic for 8 weeks had elevated levels of hepatic glutathione[149]. Thus,
arsenic exposure may evoke a compensatory increase in glutathione synthesis in the liver,
at least in response to these relatively short exposures. The increase in cysteine observed
in the current study could reflect increased uptake of this rate-limiting amino acid in an
attempt by the liver to compensate for an increased demand for glutathione synthesis.
Cysteine is taken up by the cystine/glutamate antiporter, which exchanges extracellular
cystine for intracellular gluatamate. The expression of this transporter is induced by
oxidants, electrophiles and inflammatory mediators. Therefore, the increase in cysteine
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and decrease in glutamate observed in the present study may reflect increased activity of
this transporter.
In addition to altered glycine, alterations in five other metabolites were specific to the
HFD+As group. Three of these were fatty acids or fatty acid metabolites, and each of
these was found to be decreased relative to the high fat diet alone. The high fat diet used
in this study contained 21% (w/w) milk fat. The major fatty acids found in milk fat are
palmitic acid (C16:0, 30% of the fatty acids), stearic acid (C18:0, 12%), myristic acid
(C14:0, 11%) and lauric acid (C12:0, 3.3%) [150]. We observed an increase in myristic
acid in the livers of mice fed a high milk fat diet when compared to the mice fed the low
fat control diet, but not palmitic, stearic or lauric acids.
Interestingly, when mice were co-exposed to arsenic and a high fat diet, there was a
decline in hepatic lauric acid levels. Diets high in saturated medium chain fatty acids,
such as lauric acid, protect against inflammatory liver injury caused by chronic alcohol
ingestion[151] or acute endotoxin administration[152]. Recently, in a model of
non-alcoholic fatty liver disease where rats were fed diets supplying 70% of calories from
fat, replacing fat from corn oil with fats enriched in medium-chain triglycerides
decreased steatosis and liver injury[153]. The mechanisms by which medium-chain lipids
in general and lauric acid in particular inhibit inflammatory liver injury are not clear. In
fact, some in vitro studies have found that lauric acid can by pro-inflammatory. For
example, lauric acid increased inflammatory cytokine production by astrocytes and
macrophages via activation of TLR4 signaling[154,155], but it had no effect on cytokine
production by adipocytes or endothelial cells[156,157]. It is possible that hepatic lauric
acid contributes to inflammatory liver injury independently of any effects on cytokine
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production; its levels may influence responses to cytokines, or it may be a marker of
alterations in other critical pathways like mitochondrial fatty acid oxidation[158].
Additional studies will be needed to determine how arsenic and a high fat diet contribute
to the down-regulation of lauric acid, and whether this down-regulation contributes to
increased inflammation and/or injury in this model.
Two other fatty acid metabolites were decreased in the livers of mice fed arsenic and a
high fat diet: 2-hydroxybutyrate and 2-aminobutyrate. Both of these compounds can be
produced by the catabolism of threonine, and 2-hydroxybutyrate can also be formed in
the conversion of methionine to cysteine in the transsulfuration pathway. A decrease in
serum 2-hydroxybutyrate was recently reported in children with cystic fibrosis[159], a
disease associated with increased inflammation.

It remains to be determined whether

decreases in these metabolites are common to early stages of inflammatory tissue injury.
The decrease in glycine in the HFD+As group relative to the HFD group may be an
important clue as to the mechanism by which the combination of arsenic and a high fat
diet leads to inflammatory liver injury. Glycine supplementation protects the liver in a
number of inflammatory injury models[160,161] by acting on glycine-gated chloride
channels on Kupffer cells to inhibit inflammatory cytokine production[160,162,163]. The
glycine deficiency in our model may have promoted pro-inflammatory signaling. In
support of this, we observed a dramatic increase in the number of activated Kupffer cells,
as determined by F4/80 staining, in response to arsenic exposure in the HFD group[131].
It is unclear how arsenic and a high fat diet deplete hepatic glycine, but altered glycine
metabolism could play a role. Threonine dehydratase is inhibited by cysteine[164], which
is elevated by arsenic and a high fat diet, both alone and in combination. Serine
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hydroxymethyltransferase has an active site cysteine as well as two closely-spaced
(vicinal) surface-exposed cysteines that can alter activity when modified by sulfhydryl
reagents[165, 166]. Arsenic binds to vicinal dithiols[167], but it is not known whether
serine hydroxymethyltransferase is a target of arsenic binding.
Metabolomics is a powerful approach for the discovery of pathways altered by
environmental and dietary exposures related to disease. When used to investigate the
combined effects of a high fat diet and arsenic in producing fatty liver with inflammation
and cell death, metabolomic analyses revealed significant changes in the metabolism of
short-chain and medium-chain fatty acids, as well as alterations in the pathways
producing the anti-inflammatory amino acid glycine. Further investigations into the
mechanisms by which these pathways are altered and the specific roles they play in the
progression of non-alcoholic fatty liver disease are warranted.
Metabolites in mouse liver can have very diverse chemical characteristics. In this work,
metabolites were extracted by water and methanol. Most of the nonpolar metabolites
were lost during this analytical step. The extracted metabolites were then analyzed on
GC×GC-TOF MS. Even though the GC×GC-TOF MS has a large separation power, it may
not be enough to resolve all metabolites, resulting overlapping chromatographic peaks that
introduces significant challenges for metabolite identification and quantification. In this
work, metabolite identification was first achieved by matching the experimental mass
spectra to the mass spectra recorded in the NIST mass spectral library. The incompleteness
of the existing mass spectral library does not only introduce a certain degree of
false-positive identifications, but also leaves a number of chromatographic peaks without
any compound identification. All of these technical limitations in the current study prevent

95

us from seeing the entire picture of the metabolite profile in mouse liver. Further studies
such as using different extraction methods, combining both GC×GC-TOF MS and 2D
LC-MS, and applying multiple mass spectral libraries for metabolite identification may
provide more comprehensive results. Further studies with a larger sample size will be also
necessary to confirm the results in this study.
The high accuracy of clustering between sample groups HFD vs. LFD, HFD+As vs. HFD
and LFD+As vs. LFD indicates that the high-fat diet and arsenic contaminated water can
significantly change the metabolite profile in mouse liver. Comparing the clustering
accuracy of (A) and (B), the low value of overall clustering accuracy for clustering all four
sample groups in (A) was mainly caused by a ceartin degree of similarity of metabolite
profile between sample groups LFD+As and HFD+As.

4.5. Conclusions
GC×GC-TOF MS was used to identify metabolites that were significantly increased or
decreased in the livers of mice fed a Western diet (a diet high in fat and cholesterol) and
co-exposed to arsenic-contaminated drinking water, to investigate potential mechanisms of
this diet-environment interaction. The results showed that there are distinct hepatic
metabolomic profiles associated with eating a high fat diet, drinking arsenic contaminated
water, and the combination of the two. Among the metabolites that were decreased when
arsenic exposure was combined with a high fat diet were hepatoprotective short chain and
medium-chain fatty acid metabolites and the anti-inflammatory amino acid glycine.
These results are consistent with the observed increase in inflammation and cell death in
the livers of these mice and point to potentially novel mechanisms by which these
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metabolic pathways could be altered by arsenic in the context of diet-induced fatty liver
disease.
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CHAPTER 5
HEPATIC AND FECAL METABOLOMIC
ANALYSIS OF THE EFFECTS OF
LACTOBACILLUS RHAMNOSUS GG ON
ALCOHOLIC FATTY LIVER DISEASE IN MICE
5.1. Introduction
Lactobacillus rhamnosus GG (LGG), a strain of the bacterium, Lactobacillus rhamnosus,
has a great affinity for human intestinal mucosal cells. Previous studies in our laboratory
and others demonstrated that LGG is effective in the treatment of alcohol-induced liver
injury in rodents[168-171]. More recently, we have shown that LGG culture supernatant
(LGGs) is effective in prevention of acute and chronic alcohol exposure-induced fatty
liver[172,173]. LGGs administration markedly attenuates the effects of alcohol exposure
on intestinal barrier dysfunction, by increasing intestinal mucus factors and epithelial
tight junction protein expression, leading to decreased circulation endotoxin levels. In
addition, LGGs activates hepatic 5' adenosine monophosphate-activated protein kinase-α
(AMPKα) phosphorylation, which is critical for liver lipid degradation[174].
To gain insight into the metabolic mechanisms by which LGGs exerts an influence in
alcoholic liver disease (ALD), investigation of metabolome alteration using high
throughput metabolomics analysis is needed. Comprehensive two-dimensional gas
chromatography time-of-flight mass spectrometry (GC×GC–TOF MS) is a powerful
analytical platform in metabolomics. It uses two distinctly different capillary GC columns
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of different polarities connected via a thermal modulator[137,138,175]. The analytes
co-eluted from the first column are further separated in the second column because of the
difference of column temperature and the chromatographic polarities. The further
separated analytes are detected by a time-of-flight mass spectrometer. The GC×GC–TOF
MS platform has significant advantages for complex sample analysis including: an
order-of-magnitude increase in separation capacity, significant increase in signal-to-noise
ratio and dynamic range and improvement of mass spectral deconvolution and similarity
matches[176-178].
The objectives of this study were to determine if the beneficial effects of LGGs
administration on the prevention of ALD are associated with alterations in metabolic
profiles in the liver and fecal metabolome. Male C57BL/6 mice were pair-fed either an
isocaloric control diet (PF) or alcohol-containing diet (AF) for 4 weeks with or without
LGGs co-exposure. Liver and fecal samples were collected at the end of the experiments.
The metabolite extracts from mouse livers and feces were analyzed on GC×GC–TOF MS
for metabolic profiling.

5.2. Experimental Methods
5.2.1.

Animals and Diets

C57BL/6 male mice obtained from Harlan (Indianapolis, IN) were fed a modified
Lieber-DeCarli liquid diet (Research Diet, New Brunswick, NJ). Mice were fed
EtOH-containing diets (35% of total calories, AF) ad libitum for 4 weeks. Control mice
were pair-fed isocaloric diet in which EtOH was replaced with maltose-dextrin. LGG was
cultured following the instruction provided by ATCC (Manasses, VA). The culture
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supernatant was collected when LGG bacterial growth reached 109 CFU/ml. The LGG
supernatant (LGGs) was added to the liquid diet at a dose equivalent to 109
CFU/mouse/day. At the end of the experiment, the mice were anesthetized, and the fecal
samples and liver samples were harvested. A portion of liver samples was fixed in
formalin, while the rest of the liver samples and the fecal samples were frozen
immediately in liquid nitrogen and stored at -80 ºC for later assays. The animal protocol
was approved by the University of Louisville Institutional Animal Care and Use
Committee.

5.2.2.

Liver Oil Red O Staining and Liver Total Free Fatty Acid
Analysis

Frozen liver sections were processed for staining with Oil red O and then studied by light
microscopy. Hepatic free fatty acid levels were measured using Infinity kits (Thermo
Scientific, Waltham, MA).

5.2.3.

Metabolite Sample Preparation

Fecal sample was first weighed and ground on ice. Each grounded fecal sample was
added ice cold 80% methanol with a ratio of 50 mg feces in 1 mL 80% methanol. The
mixture was vortexed for 10 min followed by centrifugation for 10 min at 16000 rpm.
The supernatant 200 µL was aspirated into a plastic tube and dried by SpeedVac
overnight. The dried metabolite extracts were dissolved in 30 µL ethoxyamine
hydrochloride solution (30 mg/mL) and vigorously vortex-mixed for 1 min.
Ethoxymation was carried out at 70 °C for 1 hour. After adding 30 µL
N-(tert-butyldimethylsilyl)-N methyltrifluoroacetamide (MTBSTFA) mixed with 1%
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tert-Butyldimethylchlorosilane (TBDMSCI), derivatization was carried out at 70 °C for 1
hour.
To prepare liver samples, a sample of liver tissue was weighed and then homogenized for
2 min after adding water at a ratio of 100 mg liver tissue/mL water. The homogenized
sample was then stored at –80 °C until use. A 100 µL aliquot of the homogenized liver
sample and 400 µL methanol were mixed and vortexed for 1 min followed by
centrifugation at room temperature for 10 min at 15000 rpm. 400 µL of the supernatant
was aspirated into a plastic tube and dried by N2 flow. The metabolites extracts were then
dissolved in 40 µL ethoxyamine hydrochloride solution (30 mg/mL) and vigorously
vortex-mixed for 1 min. Ethoxymation and derivatization were achieved in the same way
as for the fecal samples.
In order to verify the compound identification, a total of 61 compound standards were
prepared in equal molarity and analyzed on GCGC–TOF MS. The ethoxymation and
derivatization of the fecal sample, liver sample, and compound standards were carried out
right before GCGC–TOF MS analysis, respectively.

5.2.4.

GCGC–TOF MS Analysis

The LECO Pegasus 4D GC×GC–TOF MS instrument was equipped with an Agilent
6890 gas chromatograph and a Gerstel MPS2 auto-sampler (GERSTEL Inc., Linthicum,
MD), featuring a LECO two-stage cryogenic modulator and secondary oven. The primary
column was a 60 m × 0.25 mm 1dc × 0.25 μm 1df, DB-5ms GC capillary column (phenyl
arylene polymer virtually equivalent to a (5%-phenyl)-methylpolysiloxane). A second
GC

column

of

1

m

×

0.25

mm

1

dc

×

0.25

μm

2

df,

DB17ms

((50%-phenyl)-methylpolysiloxane) was placed inside the secondary GC oven after the
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thermal modulator. Both columns were obtained from Agilent Technologies (Agilent
Technologies J&W, Santa Clara, CA). The helium carrier gas (99.999% purity) flow rate
was set to 2.0 mL/min at a corrected constant flow via pressure ramps. The inlet
temperature was set at 280 °C. The primary column temperature was programmed with
an initial temperature of 60 °C for 0.5 min and then ramped at 5 °C /min to 280 °C and
kept for 15 min. The secondary column temperature program was set to an initial
temperature of 70 °C for 0.5 min and then also ramped at the same temperature gradient
employed in the first column to 280 °C accordingly. The thermal modulator was set to
+15 °C relative to the secondary oven, and a modulation time of PM = 2 s was used. The
mass range was set as 29−800 m/z with an acquisition rate of 200 mass spectra per second.
The ion source chamber was set at 230 °C with the transfer line temperature set to 280 °C,
and the detector voltage was 1450 V with electron energy of 70 eV. The acceleration
voltage was turned on after a solvent delay of 675 s. The split ratio was set at 40:1 for
liver samples and 10:1 for fecal samples.

5.2.5.

Data Analysis

The GC×GC–TOF MS data were processed using LECO’s instrument control software
ChromaTOF for peak picking and tentative metabolite identification, followed by peak
merging, retention index filtering, peak list alignment, normalization, and statistical
significance test using MetPP[141]. Two-way ANOVA test with a threshold of false
discovery rate p < 0.05 was used to determine whether a metabolite has a significance
difference of abundance level between sample groups.
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For metabolite identification using ChromaTOF, each chromatographic peak was
tentatively assigned to a metabolite if its experimental mass spectrum and a NIST11 MS
library spectrum have a spectral similarity score higher than 600 (the maximum value of
spectral similarity was defined as 1000 in ChromaTOF). If a chromatographic peak was
tentatively assigned to a metabolite by mass spectral matching, the other top four ranked
metabolite candidates were considered as the identification results of mass spectral
matching for this chromatographic peak. The tentatively assigned metabolites were
further filtered by retention index matching using iMatch software with a p-value
threshold of p < 0.001[179]. To further verify the identification of metabolites detected
with significant abundance difference between sample groups, the authentic standards of
these metabolites, if commercially available, were analyzed on GC×GC–TOF MS under
the same experimental conditions as the biological samples analyzed. A tentative
metabolite assignment was considered as a correct identification only if the experimental
information of the authentic metabolite agrees with the corresponding information of the
chromatographic peak in the biological samples, i.e., difference of the first dimension
retention time ≤ 10 s, difference of the second dimension retention time ≤ 0.05 s, and the
mass spectral similarity ≥ 700.

5.3. Results
Four biological sample groups were formed in this study, pair-fed control mice without
LGGs supplementation (PF-0, n = 5); pair-fed control mice with exposure to LGGs (PF-l,
n = 7); alcohol fed mice without LGGs supplementation (AF-0, n = 4); and alcohol fed
mice with LGGs supplementation (AF-l, n = 6). Metabolite identification was done in
three sequential steps as described in our previous work, including mass spectral
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matching, retention index matching, and comparison with authentic standards[16]. We
compared the metabolic profile differences between PF-0 and AF-0, PF-1 and PF-0, and
AF-1 and AF-0 in mouse liver and fecal samples, respectively.
GC×GC–TOF MS instrument data provide four pieces of information for each metabolite,
the first dimension retention time 1tR, the second dimension retention 2tR, fragment ion
m/z, and peak height of each fragment ion. The information of fragment ion m/z and peak
height forms the mass spectrum of the metabolite. Figure 20 is a contour plot of the
GC×GC–TOF MS data acquired from a fecal sample randomly selected from sample
group PF-0. Each chromatographic peak in Figure 20 is composed of many data points,
where the number of data points in each chromatographic peak depends on the size of the
chromatographic peak. The color of each data point is the signal intensity, i.e., the total
ion current of all fragment ions in the corresponding mass spectrum. The inset in Figure
20 demonstrates the increased separation power of GC×GC–TOF MS system. The two
chromatographic peaks have identical retention time in the first dimension GC, but are
completely separated from each other on the second dimension GC. Therefore, these two
chromatographic peaks will co-elute on a GC-MS system and generate a mixed mass
spectrum, which may induce false identification and quantification.
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Figure 20. Sample GC×GC–TOF MS chromatogram of metabolite extract from mouse
fecal samples. The x-axis is the first dimension retention time 1tR in seconds. The y-axis is the
second dimension retention time 2tR in seconds. The color bar shows the signal intensity of
each peak plotted on the chromatogram in total ion current.

By setting spectral similarity threshold to ≥ 600 in ChromaTOF, 440-1100 and 490-840
and metabolites were respectively identified from the liver and fecal samples. The
numbers of metabolites detected in liver samples and fecal samples were further reduced
to 390-880 and 435-727 after retention index matching. After cross sample alignment and
removing chromatographic peaks detected in blank samples, 236 metabolites presented in
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more than 75% of liver samples in at least one sample group, while 212 in the fecal
samples.
Two-way ANOVA tests were employed to recognize metabolite with significant
abundance changes between sample groups contributed by alcohol, LGGs, or their
interaction. A term fold-change was defined as the ratio of the large abundance value
(peak area) of a metabolite in one group divided by the small abundance value of the
same metabolite in the other group. The positive sign and negative sign indicate the
abundance increase and decrease in the testing sample group compared to the reference
sample group, respectively.
Figure 21A is an example of the metabolite abundance level changes detected in the liver
samples. Abundance distribution of the metabolite, hexanoic acid, in liver samples was
detected in the four sample groups, PF-0, PF-1, AF-0 and AF-1. Hexanoic acid (caproic
acid), a natural fatty acid existing in all mammals, has been shown to be beneficial in
high density lipoprotein synthesis in the liver. Compared with the abundance level of this
metabolite in control group PF-0, the level of this metabolite was increased with a fold
change of 1.56 in group AF-0, and 1.09 fold decrease in group PF-1. Comparing its
abundance levels between groups AF-1 and AF-0, this metabolite is decreased with a fold
change of 1.23 in the AF-1 group. The p-values for the factors of alcohol, LGGs, and
their interaction are 0.002, 0.24, and 0.80, respectively. The alcohol factor has the
smallest p-value of 0.002, indicating that this metabolite (hexanoic acid) has a significant
alteration in abundance level in mouse livers because of the alcohol factor, while LGGs
alone (p = 0.24) and the interaction of LGGs and alcohol (p = 0.80) did not significantly
change the abundance level of this metabolite in liver.
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Figure 21B depicts the abundance distribution of the same metabolite (hexanoic acid) in
feces among the four sample groups. The trend of abundance distribution of this
metabolite in fecal samples is completely different from that in the liver samples.
Compared with the abundance of this metabolite in control group PF-0, the abundance
level of this metabolite is decreased 1.54 fold in group PF-1 and by a1.25 fold decrease in
sample group AF-0. Hexanoic acid is increased with a fold change of 1.58 in group AF-1
compared to AF-0. The p-values of alcohol, LGGs, and their interaction are 0.05, 0.92,
and 0.003, respectively. The large p-value of 0.92 indicates that LGGs alone did not
significantly alter the abundance level of this metabolite in the mouse fecal metabolome,
while alcohol alone affected the abundance level of this metabolite (p = 0.05).
Importantly, the smallest magnitude of p-value (p = 0.003) for the interaction between
alcohol and LGGs indicates that the abundance level of this metabolite was significantly
changed owing to the synergistic effect of alcohol and LGGs on mouse fecal
metabolome.
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Abundance distribution of metabolite hexanoic acid in four sample groups. (A)
is in liver samples, and (B) is in fecal samples.

Table 11 lists all metabolites that were detected with significant abundance changes from
liver samples between the four sample groups with a threshold of p ≤ 0.05. These
compounds include eight free fatty acids, six amino acids, three other acids and three
other small compounds. Among the eight fatty acids, one is short chain fatty acid (SCFA,
acetic acid), two are medium chain fatty acids (MCFA, hexanoic acid and dodecanoic
acid), one long chain fatty acid (LCFA, tetradecanoic acid), two monounsaturated fatty
acids (trans-9-octadecenoic acid and cis-9-hexadecenoic acid) and two polyunsaturated
fatty acids (mead acid and arachidonic acid). The abundance levels of all four saturated
fatty acids and cis-9-hexadecenoic acid were increased when the mice were fed with
alcohol (column FC-2 in Table 11). However, the abundance levels of these acids were
all decreased when the alcohol fed mice were also exposed to LGGs (column FC-1 in
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Table 11). Figure 22 depicts the results of total free fatty acid analysis, showing that the
total non-esterified fatty acids were increased by alcohol exposure and decreased by
LGGs supplementation. Histological examination confirmed our metabolomics finding
that hepatic fat accumulation by alcohol was markedly increased, and LGGs
supplementation prevented it (Figure 23).
Among six amino acids, the abundances of five amino acids including
L-proline, L-threonine, L-phenylalanine

L-isolucine,

and L-valine were decreased when mice were

exposed to alcohol alone (column FC-2 in Table 11), while they all increased when the
alcohol fed mice were exposed to LGGs (column FC-1 in Table 11).

Table 11. Metabolites with significant changes of abundance level among the four liver
sample groups.
CAS

1

2

FC-1a

FC-2b

FC-3c

p-1d

p-2e

p-3f

Acetic acid g

67226-76-0

1443

1.01

-1.05

2.05

1.22

1.3E-03

9.0E-01

2.9E-01

Dodecanoic acid

143-07-7

1961

1.04

-1.41

1.59

-1.09

8.9E-03

7.6E-02

4.7E-01

Hexanoic acid

142-62-1

1113

1.00

-1.23

1.56

-1.09

2.1E-03

2.4E-01

8.1E-01

Tetradecanoic acid

4544-63-8

2196

1.06

-1.62

1.42

1.20

9.0E-01

4.4E-01

4.4E-02

cis-9-Hexadecenoic
acid g

373-49-9

2385

1.11

-1.40

2.25

1.26

8.2E-03

9.9E-01

1.0E-01

trans-9-Octadecenoi
c acid g

112-79-8

2594

1.17

-2.44

-1.28

-2.28

3.6E-01

3.1E-02

8.5E-01

Mead acid g

20590-32-3

2793

1.51

1.01

1.82

1.59

3.5E-02

2.7E-01

1.7E-01

Arachidonic acid g

506-32-1

2762

1.51

1.35

-1.55

1.10

1.7E-02

7.9E-02

4.0E-01

Name

tR (s)

tR (s)

Fatty acids

Amino acids
L

-Isoleucine

73-32-5

1748

0.99

1.43

-1.09

1.20

1.0E+00

3.9E-03

2.8E-01

L

-Proline

147-85-3

1803

1.08

1.33

-1.46

1.13

1.7E-03

2.2E-02

2.5E-01

L

-Threonine

72-19-5

1769

1.05

1.20

-1.08

-1.18

7.1E-05

1.4E-01

1.3E-02

63-91-2

2189

1.16

1.28

-1.10

1.31

3.2E-01

2.8E-02

9.9E-01

L-Phenylalanine
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L-Tyrosine

60-18-4

2768

1.38

1.22

1.02

1.20

6.6E-01

1.6E-02

8.8E-01

L-Valine

72-18-4

1652

0.99

1.34

-1.06

1.16

9.7E-01

3.0E-02

4.8E-01

2835-81-6

1585

0.99

-2.16

3.57

-1.14

2.5E-04

1.3E-01

8.0E-02

Glycolic acidg

79-14-1

1443

1.01

-1.05

2.05

1.22

1.4E-03

9.0E-01

2.9E-01

α-thylphenylacetic
acidg

90-27-7

2499

1.29

1.30

-2.39

1.04

9.6E-04

3.7E-01

7.2E-01

3Pyridinolg

109-00-2

1245

1.20

-1.18

1.43

1.46

3.3E-01

2.8E-01

1.2E-02

Hypoxanthineg

68-94-0

2345

1.43

-1.09

1.55

1.26

3.2E-03

5.1E-01

9.4E-02

2-(2-(2-ethoxyethox
y)ethoxy)acetic acidg

16024-58-1

2456

1.05

4.20

-4.04

1.14

4.3E-03

3.9E-03

1.5E-02

Other acids
2-aminobutanoic
acid

Others

a

fold change for AF-1 to AF-0. bfold change for AF-0 to PF-0. cfold change for PF-1 to

PF-0.dp-value of factor alcohol. ep-value of factor LGGs. fp-value of the interaction of
alcohol and LGGs. gTentative identification without verification using authentic standards.

110

Figure 22.

Effect of LGGs on hepatic free fatty acid levels. Stars * refer to the amount of

total free fatty acids between two sample groups is significantly different with p < 0.05.

Table 12 lists metabolites with significant abundance changes between sample groups
detected from fecal samples with a threshold of p ≤ 0.05. A total of nine free fatty acids,
nine amino acids, two alcohols, six other acids and nine other small compounds have
significant changes in abundance level due to alcohol, LGGs or their synergetic
interaction. Among these nine fatty acids, two are short chain fatty acids (SCFA,
isovaleric acid and pentanoic acid), one MCFA (hexanoic acid), four LCFA
(heptadecanoic acid, hexadecanoic acid, nonadecanoic acid, tetradecanoic acid), one
polyunsaturated omega-6 fatty acid (9,12-octadecadienoic acid) and one omega-7
monounsaturated fatty acid (cis-9-hexadecenoic acid). Compared with abundance levels
in sample group AF-0, the abundance levels of these SCFAs, MCFAs and LCFAs in
sample group AF-l were significantly increased while the omega-7 monounsaturated fatty
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acid and polyunsaturated omega-6 fatty acid was decreased (column FC-1 in Table 12).
Even though the fold-changes of most of the fatty acids are moderate, the abundance
level of hexadecanoic acid was increased 20.6 fold in group AF-1. Among the 9 amino
acids, the abundance levels of seven were decreased in group AF-0 compared to the
group PF-0 (column FC-2 in Table 12), Among these seven amino acids, six amino acids
were increased in the alcohol and LGGs treated group AF-1 compared to in the group
AF-0 (column FC-1 in Table 12). It is interesting that the abundance level of L-Proline
was decreased in group AF-1 compared to the group AF-0, decreased in group AF-0
compared to group PF-0, and decreased in group PF-1 compared to that in group PF-0,
respectively.

Table 12.

Metabolites with significant change of abundance level among four fecal sample
groups.

CAS

1

2

FC-1a

FC-2b

FC-3c

p-1d

p-2e

p-3f

Isovaleric acid g

503-74-2

882

0.98

1.43

-2.22

1.02

1.7E-02

4.1E-01

5.5E-01

Pentanoic acid

109-52-4

957

1.00

1.67

1.26

1.96

5.7E-01

1.7E-02

5.9E-01

Hexanoic acid

142-62-1

1114

1.02

1.58

-1.25

-1.54

5.5E-02

9.2E-01

3.2E-03

Heptadecanoic acid

506-12-7

2511

1.12

1.25

-2.41

1.44

1.5E-02

1.5E-01

5.5E-01

Hexadecanoic acid

57-10-3

2396

1.10

20.6

2.04

8.74

1.3E-02

1.5E-02

6.5E-02

Nonadecanoic acid

646-30-0

2728

1.31

1.06

1.69

-1.06

1.2E-03

9.6E-01

6.2E-01

Tetradecanoic acid

544-63-8

2197

1.09

1.81

-1.41

-1.01

4.5E-01

1.6E-04

1.4E-04

cis-9-Hexadecenoic
acid g

373-49-9

2385

1.14

-2.84

1.88

1.67

4.7E-01

5.1E-01

4.8E-02

9,12-Octadecadienoi
c acid g

60-33-3

2687

1.37

-1.82

1.02

-1.88

8.8E-01

4.1E-03

6.5E-01

63-68-3

2047

1.15

1.61

-2.82

1.13

1.4E-04

4.0E-02

3.1E-01

Name

tR (s)

tR (s)

Fatty acids

Amino acids
L-Methionine
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L

-Phenylalanine
g

63-91-2

2189

1.20

1.99

-2.57

-1.13

3.6E-03

1.4E-01

4.4E-02

70-26-8

2389

1.05

8.34

-1.68

1.13

3.4E-01

1.1E-02

4.5E-02

L

-Ornithine

L

-Alanine

56-41-7

789

0.97

1.66

-1.18

1.47

3.9E-01

2.0E-02

9.1E-01

L

-Threonine

72-19-5

2101

1.01

1.04

-7.26

1.15

6.6E-06

7.9E-01

6.2E-01

L-Aspartic acid

56-84-8

2255

1.08

1.58

-1.51

-1.68

6.1E-01

9.4E-01

4.8E-02

L-Valine

72-18-4

1667

0.99

1.17

27.6

2.33

2.6E-06

4.4E-03

2.9E-02

L

-Proline

147-85-3

1803

1.11

-1.10

-1.33

-1.11

3.7E-03

2.7E-01

9.6E-01

L

-Glutamic acid

56-86-0

2381

1.10

-1.10

1.76

-1.22

3.2E-02

7.1E-01

6.6E-01

4-hydroxybenzoic
acid g

99-96-7

2231

1.19

3.12

-2.83

-1.10

1.5E-01

4.9E-02

6.0E-02

trans-Crotonic acid g

107-93-7

888

1.05

1.59

-1.31

-1.01

6.1E-01

8.9E-03

5.9E-03

p-Coumaric acid g

501-98-4

2579

1.32

1.46

2.34

-1.43

7.0E-03

7.5E-01

2.6E-01

600-18-0

1735

1.07

-1.11

3.37

1.72

2.6E-03

3.3E-01

2.4E-01

59-67-6

1509

1.28

-1.07

6.29

1.12

1.6E-05

6.7E-01

8.6E-01

123-99-9

2391

1.17

1.89

1.42

1.14

3.0E-03

5.2E-02

1.6E-01

Propylene glycol g

57-55-6

1311

0.93

1.94

-3.15

-1.10

7.9E-05

4.2E-02

1.1E-02

2-Hydroxybenzyl
alcohol g

90-01-7

1961

1.13

1.46

2.36

-1.36

6.6E-06

6.5E-01

1.3E-02

Phenol

108-95-2

1100

1.13

1.51

-2.88

-1.04

2.4E-05

1.0E-01

3.9E-02

DL-Glyceraldehyde g

56-82-6

2622

1.18

-1.60

-2.31

1.25

2.2E-02

7.7E-01

8.1E-01

Hydroxylamine g

7803-498

1076

0.94

1.58

-2.12

-1.23

1.4E-03

2.2E-01

7.1E-03

Ethanolamine,
N-acetyl- g

142-26-7

965

1.04

1.58

-1.68

-1.02

2.9E-02

7.1E-02

5.0E-02

2-(2-(2-ethoxyethoxy
)ethoxy)acetic acid g

16024-58
-1

2455

1.07

-2.49

-1.13

-1.07

2.9E-02

4.3E-01

6.1E-01

1,2-Pyrrolidinedicarb
oxylic acid, (2R)-g

106723675-2

2139

1.29

1.70

-1.08

1.22

5.3E-01

2.1E-02

4.0E-01

Urea

57-13-6

1657

1.17

1.86

2.00

1.77

8.7E-03

4.9E-02

9.0E-01

109-00-2

1061

1.14

1.94

1.83

1.32

1.1E-04

2.5E-03

8.6E-02

1927-259

2187

1.02

-1.67

2.31

-1.94

2.2E-02

1.5E-01

4.3E-01

Other acids

2-ketobutyric acid

g

Nicotinic acid g
Nonanedioic acid

g

Alcohols

Others

3-Pyridinol

g

D,L-Homoserineg
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a

fold change for AF-1 to AF-0. bfold change for AF-0 to PF-0. cfold change for PF-1 to

PF-0.dp-value of factor alcohol. ep-value of factor LGGs. fp-value of the interaction of
alcohol and LGGs. gTentative identification without verification using authentic standards.

Figure 23.

PF-0

PF-1

AF-0

AF-1

Effect of LGGs on liver fat accumulation. Hepatic cryosections were Oil red O
stained and images were acquired by light microscopy.

5.4. Discussion
Four sample groups were formed in this study to investigate the effect of alcohol, LGGs
and their interaction on the mouse liver and fecal metabolome, respectively. Figure 24
depicts clustering results of the metabolite profiles of the four liver sample groups
(Figure 24A) and four fecal sample groups (Figure 24B), using partial least squares
discriminant analysis (PLSDA). The clear separation between sample groups indicates
that significant metabolic profiling difference presents between the sample groups.
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Figure 24. Clustering of metabolite profiles using partial least squares discriminant analysis
(PLSDA). (A) is the clustering result of metabolite profiles of all liver samples and (B) is the
clustering result of all fecal samples.
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Analysis of liver samples
Excess alcohol consumption is one of the major factors in the development of fatty liver,
which is characterized by hepatic accumulation of triglyceride, cholesterol and other
types of lipids. A total of eight fatty acids were detected with significant alteration of
abundance levels among the four sample groups. The four saturated fatty acids and
cis-9-hexadecenoic acid have the same trend in alteration of abundance levels, while the
polyunsaturated fatty acid arachidonic acid has opposite direction of abundance changes.
The abundance levels of all four saturated fatty acids and cis-9-hexadecenoic acid are all
increased in liver in the mice fed with alcohol. While SCFAs are metabolized in the
mitochondria for energy production, MCFAs and LCFAs are mainly oxidized in the
peroxisome[180].The higher levels of MCFAs and the LCFAs in the livers of mice fed
alcohol strongly suggest that alcohol feeding interferes with lipid perexisomal oxidation,
which is critical for hepatic fat elimination. However, hepatic levels of these fatty acids
were significantly decreased in liver when LGGs was supplemented to alcohol-fed mice.
This agrees with our total non-esterified fatty acids analysis and the results of histological
examination of the liver sections (Figures 22 and 23). Taken together, the beneficial
effects of LGGs on liver fat accumulation are mediated, at least in part, by increasing
fatty acid peroxisomal oxidation.
Another finding in current study is the decrease of five amino acids,
L-proline,

L-threonine,

L-phenylalanine,

L-valine,

L-isoleucine,

by alcohol feeding, and the

normalization of their abundance levels by LGGs supplementation. L-threonine is an
essential amino acid which is not synthesized in mice. L-Threonine deficiency causes fat
build up in the liver, while supplementation with
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L-threonine

lowers hepatic fat

concentration. [181]. L-Proline is a nonessential amino acid which can be synthesized
from glutamate. Importantly,

L-isoleucine

is a branched-chain amino acid (BCAA),

which is an essential amino acid and plays an important role in many aspects of hepatic
physiology[182].

Clinical

studies

showed

that

BCAA

enriched

nutritional

supplementation is beneficial for the treatment of ALD[183].Our results agree with these
studies and demonstrate that LGGs supplementation increases L-isoleucine concentration
to reduce the fat buildup induced by alcohol, likely through improved intestinal
absorption. Altogether, our studies demonstrate that LGGs helps remedy the liver damage
of amino acid depletion caused by alcohol consumption.
Analysis of fecal samples
We have previously demonstrated that saturated fat supplementation protects liver from
alcohol-induced injury through stabilizing intestinal tight junctions leading to reduced
circulating lipopolysaccharide (LPS)[150]. Although the underlying mechanisms are still
unclear, recent studies showed that saturated fatty acids were metabolized by commensal
Lactobacilli to promote their expansion[184]. Fatty acids can be synthesized by bacteria
in the host in addition to being derived from the fat in the diet. In the current studies, we
fed mice with the same amount of fat in the isocaloric diet in all animal groups. Therefore,
the changes of fatty acids we observed are likely from bacterial production. The
concentrations of five of nine detected fatty acids (i.e., isovaleric acid, hexanoic acid,
heptadecanoic acid, tetradecanoic acid and cis-9-hexadecenoic acid) were significantly
reduced in the feces of mice fed alcohol. Of particular interest, hepatadecanoic acid
(C17:0), which is a LCFA produced only by bacteria[185] was reduced 2.41 folds by
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alcohol. Importantly, LGGs supplementation to both alcohol-fed and pair-fed mice
significantly increased luminal levels of hepatadecanoic acid.
Chronic alcohol exposure significantly changes the gut bacterial population[186].
Administration of probiotics to alcohol-exposed mice normalized gut microflora, restored
intestinal barrier tight junctions, reduced endotoxin translocation and attenuated liver
steatosis and inflammation[169]. The increased abundance levels of fatty acids (i.e.,
isovaleric acid, pentanoic acid, hexanoic acid, heptadecanoic acid, hexadecanoic acid,
nonadecanoic acid and tetradecanoic acid), therefore, contributes to the beneficial effects
of LGGs in the reduced fatty liver and liver injury in response to alcohol exposure.
Similar to our findings in the liver, fecal concentrations of six amino acids (L-methionine,
L-phenylalanine, L-omithine, L-alanine, L-threonine

and L-aspartic acid)

were reduced

by alcohol feeding and increased by LGGs supplementation. Proteins in the diet are
degraded in the intestine to amino acids which serve as nutrients for intestinal cells and
extraenteric tissues. Previous work demonstrated that gut microflora potentially play a
major role in the proteolysis in the large intestine. Amino acid metabolism in the host
cells depends on the types of bacteria and the amino acids. Currently, it is still unclear
how a specific amino acid is metabolized in the gut in response to alcohol exposure. The
fact that the decreased amino acid concentrations of six amino acids were increased by
LGGs supplementation suggests that the effects of LGGs on amino acid anabolism could
potentially contribute to the beneficial effects in ALD.
While metabolite regulation differences between sample groups observed in this study
are consistent with our histological study, our current work still has some limitations.
Metabolites in mouse liver and mouse feces can have very diverse chemical
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characteristics. In this work, metabolites were extracted by water and methanol. Most of
the nonpolar metabolites were lost during this analytical step. The extracted metabolites
were then analyzed on GC×GC–TOF MS. Even though GC×GC–TOF MS has better
separation power compared to the conventional one dimensional GC–MS, it may not be
enough to resolve all metabolites and may result in overlapping chromatographic peaks
which would introduce significant challenges for metabolite identification and
quantification. In this work, metabolite identification was first achieved by matching the
experimental mass spectra to the mass spectra recorded in the NIST11 MS library. The
incompleteness of the existing mass spectral library not only introduces a certain degree
of false-positive identifications, but also leaves a number of chromatographic peaks
without any compound identification. Besides the MS library, metabolite identification
GC×GC–TOF MS can also be affected by the spectral similarity measure and the optimal
weight factor used during mass spectral matching[139]. It is impossible to estimate the
rate of false-positive identifications induced by the incompleteness of the NIST11 MS
library, However, analysis of NIST MS library demonstrates that the accuracy mass
spectral matching based metabolite identification can be improved from about 80% to 96%
if the top five ranked metabolite candidates are considered as the identification
results[139]. To increase the metabolite identification accuracy of using existing NIST11
MS library, the top five ranked metabolite candidates for each chromatographic peak
were used as the results of mass spectral matching and further subjected to retention
index matching in this study. The metabolite candidate with the best retention index
matching was kept for further analysis. All of these technical limitations in the current
study prevent us from seeing the entire picture of the metabolite profile in mouse liver
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and feces. Further studies, such as using different extraction methods and combining both
GC×GC–TOF MS with two-dimensional liquid chromatography high resolution mass
spectrometry (2D LC-MS) may provide more comprehensive results.

5.5. Conclusions
GC×GC–TOF MS was used to identify metabolites that have significant alteration in their
abundance levels in mouse liver and fecal samples collected from mice fed with and
without alcohol, with and without co-exposure to LGGs. Our results show that the
abundance levels of saturated fatty acids increase in liver samples but the abundance levels
of a fraction of these fatty acids decreased in fecal samples when the mice were fed with
alcohol. However, the abundance levels of all saturated fatty acids were decreased in
mouse livers but increased in mouse feces when the mice were co-exposed to LGGs. Also
we found that alcohol consumption depletes some amino acids in mouse livers, and such
liver damage can be remedied by supplementing the mice with LGGs. These results
demonstrate that LGGs alleviates alcohol-induced fatty liver by the mechanisms involving
increasing intestinal and decreasing hepatic fatty acids and increasing amino acid
concentration.
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CHAPTER 6
SUMMARY AND CONCLUSIONS
In this dissertation we first developed a bioanalytical platform LTQ-FTICR MS coupled
with DI-nESI and the associated bioinformatic platform MetSign for metabolite biomarker
discovery. We further applied the developed platforms for metabolite biomarker discovery
and mechanistic studies including the analysis of Triacylglycerols Using High-Resolution
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Mass Spectrometry in Combination with in vivo Metabolite Deuterium Labeling;
Metabolomic Analysis of the Effects of Polychlorinated Biphenyls in Non-Alcoholic Liver
Disease.
The obvious disadvantage of direct infusion MS is easily getting ion suppression since
there is no separation before detection. However, LTQ-FTICR MS has the advantages of
high sensitivity and accuracy, wide dynamic range, and the ability to identify metabolites
from complex samples. Also, chip-based nano-spray ESI ionization can get rid of carry
over. In chapter 2, we profile all measurable metabolites. Metabolites were extracted based
on Bligh & Dyer’s method to cover both polar and non-polar metabolites. In chapter 3, we
focus on triglycerides. Thus chloroform: methanol (2:1) was used for lipid extraction.
After extraction, we optimized the instrument parameter settings and applied it to analyze
biological sample.
MetSign software code was written by bioinformatics specialist from our group. The
software has assignment and quantitative analysis function. During assignment analysis,
one m/z value gives more than one candidate. To narrow down the identification candidate,
we used mass frontier software to get the theoretical MS/MS spectrum. At the same time,
we did experiment to get the MS/MS spectrum of this particular m/z. By matching the
similarities between the experimental spectrum and the theoretical MS/MS spectrum, we
get the best matching ID. Then authentic standard was purchase and analyzed to get
MS/MS spectrum to confirm our identification. By following this procedure, identification
accuracy was greatly improved.
Also I conducted spike-in experiments to test the identification and quantitative accuracy.
The standard provided the identification information required to test our identification
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accuracy. Spiking with different concentrations of standards provided quantitative results
to test our accuracy of quantitative analysis. Overall, we improved the identification
accuracy and quantitative accuracy of the direct infusion MS platform allowing it to be
applied to biomarker discovery. However, biomarker clinical studies were not performed
and the biomarker has not been validated in this work.
In Chapter 2, we applied the developed platform to metabolomic analysis of the effects of
polychlorinated biphenyls in non-alcoholic liver disease. We found several significant
changes in molecules for different group comparisons. Notably, erythronic acid had the
largest abundance change with a 28.8-fold increase in the HFD+PCB 153 group when
compared to the HFD group. GSH had a 5.91-fold decrease in the HFD+PCB 153 group
and its conjugate, S-(hydroxymethyl)glutathione had a 2.97-fold decrease. Based on these
results, antioxidant depletion is likely to be an important consequence of this interaction.
Our metabolomics study can give more detailed information and even demonstrate some
mechanisms by comparing histological studies.
In Chapter 3, we applied the developed platform combing with in vivo Metabolite
Deuterium Labeling to study deuterium labeled triglycerides. Deuterium labeling water
was used to feed mice, which make sure triglycerides in liver will be deuterium labeled.
After 5 weeks feeding, normal water will be used to feed mice. Liver tissue and white
adipose tissue were both collected to study. Time course study were also conducted, the
mice were sacrificed after 2 weeks feeding or after 4 weeks feeding. We found that
deuterated triacylglycerols (TGs) were significantly increased in alcohol induced fatty
liver at two and four weeks of alcohol feeding periods, Also found that deuterated TGs
were significantly decreased in both eWAT and sWAT at the two and four weeks. The
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increase of deuterium incorporated TGs in alcohol-induced fatty liver and their decrease in
both eWAT and sWAT indicate that alcohol exposure induces hepatic influx of fatty acids
which are released from WATs. The time course results further indicate a mechanistic link
between adipose fat loss and hepatic fat gain in alcoholic fatty liver. This mechanism
cannot be found only by histological study. Deuterium labeling combining with our
analytical platform were combined together to demonstrate the mechanism.
We also successfully developed a GC×GC-TOF MS bioanalytical platform and MetPP
bioinformatics platform for metabolomic profiling, and applied them to metabolite
biomarker discovery including the effects of Chronic Arsenic Exposure in a Mouse Model
of Diet-induced Fatty Liver Disease; Hepatic and Fecal Metabolomic Analysis of the
Effects of Lactobacillus Rhamnosus GG on Alcoholic Fatty Liver Disease in Mice.
GC×GC was originally described in 1991. However, the system is still not that widely used
mainly due to two reasons. One is the system is much complicated, another reason is the
bottleneck of processing high throughput of GC×GC MS data. GC×GC–TOF MS
comparing with GC –TOF MS, it increased peak capacity, peak resolution, peak sensitivity,
dynamic range, signal to noise ration when the system is optimized. However, the system is
more complicated comparing with GC-TOF MS. A lot of parameters including column
configuration including column stationary phase, column length, column width,
temperature gradient, temperature offset of two column, flow rate, hot and cold pulse time
ratio, modulation period will affect the separation power of the system. It is very critical to
optimize all the parameters to get good metabolites coverage before sample analysis. We
optimized each parameter based on peak resolution, detection limit, whether wrap around
exist or not.
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For data processing, currently commercially software like ChromaTOF can do peak
picking and tentative metabolite identification based on similarity between EI spectrum
with NIST database. However, there is relative high rate of false identification. Retention
index matching was performed using iMatch software with p-value threshold set as p ≤
0.001, which use the information of retention time based on chemical property. Parts of the
identified metabolites were confirmed by the first dimension retention index matching and
parts were also preserved due to the lack of retention index information in the NIST11
retention index database. However, amount of the mass spectral matched metabolites were
removed due to the large first dimension retention index deviation from the database values.
This will decrease ratio of false identification. After this step, commercially available
authentic standards were also purchased and analyzed to get spectrum to confirm our
identification. Some metabolites were tentatively assigned if there are no commercially
available standards. Tentatively-identified metabolites were considered as false
identifications and removed from the identification list, if they were recognized as drugs or
from non-mammalian animals during metabolic network analysis by the Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA).
Spike-in experiments were also carried out to test the identification and quantitative
accuracy. The standard can give the identification information to test our identification
accuracy. Spiking with different concentration of standards can provide quantitative results
to test our accuracy of quantitative analysis.
In Chapter 4, we applied the developed platform to metabolomic analysis of the effects of
chronic arsenic exposure of diet induced fatty liver disease. We optimized our system
before our sample analysis and we did spike-in experiment to test the accuracy of
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identification and quantitation before sample analysis. A high value of AUC indicates a
high accuracy of recognizing the concentration difference of the spiked-in compounds
between sample groups.
We found that the high fat diet significantly altered nine metabolites and the addition of
arsenic resulted in further alterations in three of these metabolites. The HFD-induced
increase in cysteine was amplified, whereas the increase in glutamate was blocked, by
co-exposure to arsenic. Also, the HFD-induced decrease in lysine was reversed by arsenic.
Glycine was decreased by the combination of arsenic and a high fat diet. Therefore, all
three of the amino acids that constitute the antioxidant glutathione (glutamate, cysteine and
glycine) were altered, with glutamate and glycine levels lower and cysteine levels higher.
The results showed that there are distinct hepatic metabolomic profiles associated with
eating a high fat diet, drinking arsenic contaminated water, and the combination of the two.
Among the metabolites that were decreased when arsenic exposure was combined with a
high fat diet were hepatoprotective shortchain and medium-chain fatty acid metabolites
and the anti-inflammatory amino acid glycine. These results are consistent with the
observed increase in inflammation and cell death in the livers of these mice and point to
potentially novel mechanisms by which these metabolic pathways could be altered by
arsenic in the context of diet-induced fatty liver disease.
In Chapter 5, the platforms were applied to hepatic and fecal metabolomic analysis of the
effects of LGG on alcoholic fatty liver disease in mice. Analysis of NIST MS library
demonstrates that the accuracy mass spectral matching based metabolite identification can
be improved from about 80% to 96% if the top five ranked metabolite candidates are
considered as the identification results. To increase the metabolite identification accuracy
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of using existing NIST11 MS library, the top five ranked metabolite candidates for each
chromatographic peak were used as the results of mass spectral matching and further
subjected to retention index matching.
Fecal sample and liver sample were both collected. After analysis, we found that saturated
fatty acids increase in liver samples, but decreased in fecal samples when the mice were fed
with alcohol. However, all saturated fatty acids were decreased in mouse livers but
increased in mouse feces when the mice were co-exposed to LGGs. Alcohol consumption
depletes some amino acids in mouse livers, and such liver damage can be remedied by
supplementing the mice with LGGs. It demonstrates that LGGs alleviates alcohol-induced
fatty liver by the mechanisms involving increasing intestinal and decreasing hepatic fatty
acids and increasing amino acid concentration.
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APPENDIX
LIST OF ABBREVIATIONS
AF: Alcohol-containing Diet
AFLD: Alcoholic Fatty Liver Disease
ALT: Plasma Alanine Aminotransferase
AMPKα: Adenosine Monophosphate-activated Protein Kinase-α
AUC: Area Under Curve
BCAA: Branched-chain Amino Acid
BHT: Butylatedhydroxytoluene
CD: Control Diet
CID: Collision-induced Dissociation
DI-MS: Direct Infusion Mass Spectrometry
DI-nESI: Direct Infusion Chip-based Nano-electrospray Ionization
eWAT: epididymal White Adipose Tissue
FDR: False Discovery Rate
FFA: Free Fatty Acids
FLD: Fatty Liver Disease
FN: False-negative
FP: False-positive
FTICR-MS: Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
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GC×GC-TOF MS: Two-dimensional Gas Chromatography Time-of-flight Mass
Spectrometry
GC-MS: Gas Chromatography Mass Spectrometry
GMM: Gaussian Mixture Model
GSH: Glutathione (GSH)
HFD: High Fat Diet
HILIC: Hydrophobic Interaction Liquid Chromatography
HMDB: Human Metabolome Database
HSL: Hormone Sensitive Lipase
IPA: Ingenuity Pathway Analysis
KEGG: Kyoto Encyclopedia of Genes and Genomes
LCFA: Long Chain Fatty Acid
LC-MS: Liquid Chromatography Mass Spectrometry
LGG: Lactobacillus Rhamnosus GG
LIT: Linear Ion Trap
LPS: Lipopolysaccharide
LTQ-FTICR MS: Linear Trap Quadruple - Fourier Transform Ion Cyclotron Mass
Spectrometer
M: Molar
mg: milligram
mL: milliliter
mmol: millimole
MS: Mass Spectrometry
NAFLD: Non-alcoholic Fatty Liver Disease
NASH: Non-alcoholic Steatohepatitis
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NCE: Normalized Collision Energy
nESI: Nano-electrospray Ionization
NMR: Nuclear Magnetic Resonance
OCT: Optimal Cutting Temperature
PCB: Polychlorinated Biphenyls
PF: Isocaloric Control Diet
PPB: Parts Per Billion
PPM: Parts Per Million
PPV: Positive Predictive Value
PTEN: Phosphatase and Tensin Homolog
ROC: Receiver Operating Characteristic
ROS: Reactive Oxygen Species
RP-LC: Reverse Phase Liquid Chromatography
RP: Resolving Power
RSD: Relative Standard Deviation
SCE: Strong Cation Exchange
SCFA: Short Chain Fatty Acids
SIAM: Stable Isotope Assisted Metabolomics
SIR: Selected Ion Recording
SPF: Second-order Polynomial Fitting
SRM: Slected Reaction Monitoring
sWAT: Subcutaneous White Adipose Tissue
TGs: Triacylglycerols
TP: True-positive
TPR: True-positive Rate
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VLDL: Very Low-density Lipoproteins
WAT: White Adipose Tissue
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